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Abstract
Background: The use of warfarin in older patients requires special consideration because of concerns with
comorbidities, interacting medications, and the risk of bleeding. Several studies have suggested that warfarin may
be underused or inconsistently prescribed in long-term care (LTC); no published systematic review has evaluated
warfarin use for stroke prevention in this setting. This review was conducted to summarize the body of published
original research regarding the use of warfarin in the LTC population.
Methods: A systematic literature search of the PubMed, Cumulative Index to Nursing and Allied Health Literature,
and Cochrane Library was conducted from January 1985 to August 2010 to identify studies that reported warfarin
use in LTC. Studies were grouped by (1) rates of warfarin use and prescribing patterns, (2) association of resident
and institutional characteristics with warfarin prescribing, (3) prescriber attitudes and concerns about warfarin use,
(4) warfarin management and monitoring, and (5) warfarin-related adverse events. Summaries of study findings and
quality assessments of each study were developed.
Results: Twenty-two studies met the inclusion criteria for this review. Atrial fibrillation (AF) was the most common
indication for warfarin use in LTC and use of warfarin for stroke survivors was common. Rates of warfarin use in AF
were low in 5 studies, ranging from 17% to 57%. These usage rates were low even among residents with high
stroke risk and low bleeding risk. Scored bleeding risk had no apparent association with warfarin use in AF. In
physician surveys, factors associated with not prescribing warfarin included risk of falls, dementia, short life
expectancy, and history of bleeding. International normalized ratio was in the target range approximately half of
the time. The combined overall rate of warfarin-related adverse events and potential events was 25.5 per 100
resident months on warfarin therapy.
Conclusions: Among residents with AF, use of warfarin and maintenance of INR levels to prevent stroke appear to
be suboptimal. Among prescribers, perceived challenges associated with warfarin therapy often outweigh its
benefits. Further research is needed to explicitly consider the appropriate balancing of risks and benefits in this frail
patient population.
Background
Beginning in the year 2015, the greatest population
increases in the United States are expected to occur
among persons aged 65 years and older [1]. With
increasing age, the risk for developing thromboembolic
disease, including deep vein thrombosis (DVT), pulmon-
ary embolism (PE), myocardial infarction (MI), and
stroke increases correspondingly. Among stroke survi-
vors or patients with atrial fibrillation (AF), warfarin has
been used for prevention of thromboembolic stroke,
although among non-cardioembolic stroke survivors
without AF, antiplatelet agents are first-line therapy [2].
The use of warfarin in older patients requires special
consideration because of comorbidities such as kidney
disease and diabetes, the use of multiple and potentially
interacting medications, and the risk of bleeding, all of
which increase with age and concurrently with age-
related diseases [3-6].
A number of studies have suggested that warfarin may
be underused or inconsistently prescribed in long-term
care (LTC) facilities [7-13]. There are several reasons
this may be the case. For one, evidence-based guidelines
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clinical trials measuring the efficacy of warfarin are
rarely performed in the LTC setting. Clinicians are thus
left with incomplete evidence for generalizing study
findings from non-LTC patients to older and more frail
LTC residents [14]. Further, clinicians are likely to be
concerned about major bleeding in older patients
[14,15] and consequently reluctant to prescribe warfarin
when indicated.
To objectively reconcile issues of benefit and risk asso-
ciated with warfarin use in LTC residents and to explore
its usage in this setting, a review of the findings from
empirical research conducted in this setting is warranted.
The purpose of this review was to identify and summar-
ize the body of published original research regarding the
use of warfarin in LTC. Because the studies reviewed
here differ in purpose, articles are grouped by the most
common topics identified: (1) warfarin rates of use and
prescribing patterns, (2) association of resident and/or
facility characteristics with warfarin prescribing, (3) pre-
scriber attitudes and concerns about warfarin use, (4)
warfarin management and monitoring, and (5) warfarin-
related adverse events.
Methods
Literature search
Two investigators (MN and GR) conducted a systematic
search of the PubMed, Cumulative Index to Nursing and
Allied Health Literature (CINAHL), Cochrane Database
of Systematic Reviews (CDSR), Database of Abstracts and
Reviews of Effects (DARE) and National Health Service
Economic Evaluation Database (NHS EED) databases
(Figure 1). Title, abstract, and text searches for each data-
base were performed for the following search terms:
(anticoag* OR warfarin) AND ("long-term care” OR “nur-
sing home”). The search was repeated in PubMed using
the Medical Subject Heading (MeSH) database search
key words “nursing home” and “long-term care.” Addi-
tionally, the websites of the Agency for Healthcare
Research and Quality (AHRQ) and the American Medical
Directors Association (AMDA) were searched. A manual
review of references from each pertinent article, review
articles, and treatment guidelines was also conducted to
identify additional related articles.
Study selection
Two investigators (MN and GR) independently deter-
mined study eligibility, with disagreement resolved by dis-
cussion. A study was deemed eligible for inclusion in the
systematic review if it: (1) reported on prescribing or use
of warfarin alone or in combination with antiplatelet med-
ications in the LTC setting, (2) was published in English,
(3) was published between January 1985 and August 2010,
and (4) reported original research. Editorials, letters,
commentaries, reviews, expert opinions or clinical topic
discussions, guidelines, and case studies were excluded
from this review.
Data abstraction
For each included study, data were independently
abstracted by two investigators (MN and GR) to include
the following details: study objective, intervention/expo-
sure and outcomes, study design, data source, study popu-
lation, study setting, time period, summary of results,
funding source, and quality assessment.
Quality assessment
Two investigators (MN and GR) compiled lists of strengths
and weaknesses in the methodology of each study upon
the initial reading. Using the quality assessment methodol-
ogy for observational studies and randomized controlled
trials developed by Williams et al. for the AHRQ [16], one
investigator (GR) responded to the 11 structured closed-
ended questions regarding quality for each observational
study and the 10 structured closed-ended questions for the
single randomized controlled trial reviewed.
Results
Study identification and characteristics
The initial search of the four electronic databases
returned 273 citations, of which 41 were duplicates, leav-
ing 232 citations for abstract and full text review. Upon
review, 210 of these were excluded for failing to meet all
study selection criteria. Thus, a total of 22 studies
[7-13,17-31] were retained. These included: one rando-
mized controlled trial [20]; 10 retrospective cohort stu-
dies [8,10,11,18,19,21-23,25,30], one mixed prospective
and retrospective cohort study [24], three case-control
studies [7,26,31], and seven cross-sectional studies
[9,12,13,17,27-29].
Across all 22 studies, the total number of LTC residents
studied was 130,757, with sample sizes in individual stu-
dies ranging from 37 [31] to 53,829 [12]. Study duration
ranged from 1 month [9] to 6 years [26]. Among the
included studies, 14 reported on the rate of warfarin pre-
valence and prescribing patterns [7-13,17-21,24,25], eight
evaluated the association of resident or facility characteris-
tics with warfarin prescribing [7,8,10-13,17,18], three
reported on prescriber attitudes and concerns regarding
warfarin use [27-29], nine discussed warfarin management
and monitoring [8,9,11,22-25,30,31], and two reported on
warfarin-related adverse events [25,26]. Unless otherwise
indicated below, significance was reported at 95%
confidence.
Rate of warfarin use and prescribing patterns
Of the 14 studies (112,754 total residents) that examined
the rate of warfarin use or prescribing patterns in LTC
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residents with various conditions for which warfarin is
indicated, comparing residents who were prescribed
warfarin with those who were not prescribed warfarin.
Three of these studies [20,21,24] examined consultant
pharmacist interventions with regard to warfarin pre-
scribing in the facilities studied (Table 1 Part B).
Primary indications for warfarin therapy
AF was the primary indication for warfarin therapy in
two studies (n = 618), accounting for 74% [24] and 58%
[25] of residents receiving warfarin, respectively. Stroke
prevention without AF accounted for 12% [25], while
DVT accounted for 20% [24], PE for 6% [24], and either
DVT or PE for 26% [25] of residents receiving warfarin.
Rate of warfarin use
Eight studies (n = 22,573) [7-13,19] reported rates of war-
farin use across all residents having a condition for which
warfarin was indicated. These only included residents
having AF or previous stroke; no other indications were
described. Four of these studies (n = 2396) [7,10,12,13]
also reported the rates of use for warfarin combined with
antiplatelet therapy. Rates for warfarin use alone ranged
Figure 1 Literature search and study selection process.
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Page 3 of 33Table 1 Warfarin indications, rate of use and prescribing patterns
Study Study objective,
(intervention/
exposure and
outcomes)
Study design,
data source
Study population, study
setting, time period
Results Quality assessment, funding source
Part A: Warfarin exposure
Abdel-Latif et
al. (2005) [7]
To determine
predictors of OAC
therapy for AF in LTC
Design: case
control study
Data source:
medical chart,
pharmacy record,
and MDS
Population: 117 residents
with chronic or
paroxysmal AF identified
from 934 total residents
Setting: 6 LTC facilities
with > 100 beds in
Cleveland metropolitan
area (US)
Time period: not specified
Among 117 residents (12.5% of 934) with AF, OAC
was prescribed for 46%; aspirin or clopidogrel: 40%;
no antithrombotic treatment: 21%.
Logistic regression produced 2 independent
predictors of OAC prescription: (1) Prior stroke was
the primary determinant of receiving OAC (OR = 0.02;
95% CI = 0.09-0.47) sic, and (2) history of GI bleeding
was a predictor for not receiving OAC (OR, 5.6; 95% CI
= 1.1- 29.4). Classification and regression tree analysis
found residents with prior stroke or GI bleeding and
no history of coronary artery disease and who were
non-Caucasian were less likely to be prescribed OAC.
Those without stroke were less likely to be prescribed
OAC if they were younger, had dementia or lower
functional status
Quality assessment for observational studies:
1) Unbiased selection of the cohort? Yes
2) Selection minimizes baseline differences in
prognostic factors? Yes
3) Sample size calculated/5% difference? No
4) Adequate description of the cohort? Yes
5) Validated method for ascertaining exposure? Yes
6) Validated method for ascertaining clinical
outcomes? Yes
7) Outcome assessment blind to exposure? Yes
8) Adequate follow-up period? Yes; date of study not
specified; cross-sectional
9) Completeness of follow-up? Yes
10) Analysis controls for confounding? Yes
11) Analytic methods appropriate? Partial; MDS
cognition and functional scale scoring methods not
referenced; multivariate findings not fully reported
Funding: not specified
Christian et
al. (2003) [17]
To evaluate the
extent to which
people of color (e.g.
non-white or
Hispanic) in US
nursing homes were
less likely to receive
pharmacologic
treatment of recurrent
stroke
Design:
retrospective
cross-sectional
study
Data source: the
SAGE database
(links inpatient
Medicare claims,
drug data, and
MDS data)
Population: 19,051
nursing home residents
with recent
hospitalization for
ischemic stroke
Setting: Kansas, Maine,
Mississippi, Ohio, New
York, and South Dakota
(US)
Time period: 1992-1996
Variability in use of any treatment for secondary
stroke prevention (warfarin or antiplatelet agent) was
observed by race/ethnicity: 58% of American Indians
received therapy, 54% of non-Hispanic whites, 49% of
non-Hispanic blacks, 46% of Hispanics, and only 39%
of Asian/Pacific Islanders.
The use of warfarin among residents with conditions
warranting anticoagulant therapy was 40% among
non-Hispanic whites, 36% among American Indians,
32% among non-Hispanic blacks, 26% of Asian/Pacific
Islanders, and 25% among Hispanics. After controlling
for confounding, Asian/Pacific Islanders (prevalence
difference = -5.2, CI = -18.1 to 7.8), non-Hispanic black
residents (prevalence difference = -7.6, CI = -11.2 to
-3.9), and Hispanics (prevalence difference = -7.6, CI =
-17.6 to 2.2) received warfarin less often than non-
Hispanic whites
Quality assessment for observational studies:
1) Unbiased selection of the cohort? Yes
2) Selection minimizes baseline differences in
prognostic factors? Yes
3) Sample size calculated/5% difference? Partial; likely
lacked statistical power for Asian/Pacific Islanders,
Hispanics, and American Indians
4) Adequate description of the cohort? Yes
5) Validated method for ascertaining exposure? Yes
6) Validated method for ascertaining clinical
outcomes? Yes
7) Outcome assessment blind to exposure? Yes
8) Adequate follow-up period? No; uses data from
admission only so secondary stroke prevention was
more likely ordered at hospital discharge, not in LTC
facility
9) Completeness of follow-up? No
10) Analysis controls for confounding? Yes
11) Analytic methods appropriate? Partial; prevalence
differences reported rather than association strength
(i.e. no OR)
Funding: National Institute on Aging, AHRQ
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3Table 1 Warfarin indications, rate of use and prescribing patterns (Continued)
Gurwitz et al.
(2007) [25]
To examine the
preventability of
actual and potential
warfarin-related
adverse events in the
nursing home setting
Design:
retrospective
cohort study
Data source:
nursing home
records
Population: all 490
residents of 25 nursing
homes receiving warfarin
therapy
Setting: 25 nursing homes
(bed size range, 90-360)
in Connecticut (US)
Time period: 12- month
observation period (Apr
2003 - Mar 2004)
The most common indications for warfarin therapy
included stroke prevention in AF (58%), treatment/
prevention of DVT or PE (26%), and stroke prevention
without AF (12%)
Quality assessment for observational studies:
1) Unbiased selection of the cohort? Yes
2) Selection minimizes baseline differences in
prognostic factors? Yes
3) Sample size calculated/5% difference? Yes
4) Adequate description of the cohort? Yes
5) Validated method for ascertaining exposure? Partial;
classification of warfarin use/non-use within a given
resident-month not explicated
6) Validated method for ascertaining clinical
outcomes? Yes
7) Outcome assessment blind to exposure? Yes
8) Adequate follow-up period? Yes
9) Completeness of follow-up? Yes
10) Analysis controls for confounding? No; Did not
analyze prognostic factors associated with adverse
warfarin-related events other than warfarin exposure
11) Analytic methods appropriate? Partial; association
of resident characteristics or INR values with risk of
adverse warfarin-related event not assessed
Funding: AHRQ
Gurwitz et al.
(1997) [8]
To determine the
prevalence of AF in
the institutionalized
elderly population
and the proportion
receiving warfarin; to
identify clinical and
functional
characteristics of
institutionalized
elderly persons with
AF that are associated
with the use of
warfarin; access
quality of warfarin
prescribing and
monitoring
Design:
retrospective
cohort study
Data source:
medical record
review of
residents with ≥ 2
weeks of warfarin
therapy during
the 12-month
period preceding
the date of
medical record
abstraction
Population: 6437 residents
of LTC facilities
Setting: 30 LTC facilities
(6437 total number of
beds) located in New
England, Quebec, and
Ontario (US and Canada)
Time period: Jul 1993-Aug
1995
An electrocardiogram indicating AF was present in
the records of 7.5% of 5500 LTC residents; 32% of
such patients were being treated with warfarin. In
multivariate analysis, only a history of stroke (OR =
1.87; 95% CI = 1.20-2.91) was found to be positively
associated with the use of warfarin in this setting.
Patients with a diagnosis of dementia (OR = 0.59; 95%
CI = 0.38-0.90) and those aged _85 years (OR = 0.46;
95% CI = 0.22-0.94) were less likely to receive warfarin
therapy. Warfarin was commonly prescribed to
patients with a history of bleeding (28.5%), substantial
co-morbidity (30.8% major) and functional impairment
(25.4% severe), a history of falls (28.5%), or
concomitant potentiating drug therapy (17.7%)
Quality assessment for observational studies:
1) Unbiased selection of the cohort? Yes
2) Selection minimizes baseline differences in
prognostic factors? Yes
3) Sample size calculated/5% difference? Yes
4) Adequate description of the cohort? Yes
5) Validated method for ascertaining exposure? Yes
6) Validated method for ascertaining clinical
outcomes? Yes
7) Outcome assessment blind to exposure? Yes
8) Adequate follow-up period? Yes (cross-sectional)
9) Completeness of follow-up? Yes
10) Analysis controls for confounding? Yes
11) Analytic methods appropriate? Yes
Funding: DuPont Pharma, the National Institute on
Aging, Medical Research Council of the Province of
Quebec
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3Table 1 Warfarin indications, rate of use and prescribing patterns (Continued)
Hughes et al.
(2004) [18]
To identify factors
relating to initiation
and discontinuation
of secondary stroke
prevention agents
(warfarin and
antiplatelets) among
stroke survivors in
nursing homes.
Design:
retrospective
cohort study
Data source: MDS
for patient
characteristics
matched to the
OSCAR system for
facility
characteristics
Population: 16,579 stroke
survivors; 9547 were not
receiving any secondary
stroke prevention
treatment at admission;
6244 were receiving
therapy
Setting: nursing homes in
6 states (US)
Time period:
1992-1996: each resident
was followed ≥ 6 months
In all, 12% initiated drug therapy (warfarin or
antiplatelet); 30.3% discontinued. Conditions known to
increase the risk of recurrent stroke (e.g. AF) were
predictive of initiation. Factors inversely related to
initiation of therapy included advanced age, severe
cognitive impairment, and being dependent in ADLs.
Co-morbid conditions were inversely related to
discontinuation of treatment, whereas advanced age
and severe cognitive impairment increased likelihood
of discontinuation.
Black residents (OR = 0.62; 95% CI = 0.49-0.78) were
less likely than non- Hispanic white residents to
initiate therapy. Asian/Pacific Islanders (OR = 0.44; 95%
CI = 0.23-0.83) were less likely than non-Hispanic
white residents to discontinue therapy
Quality assessment: for observational studies:
1) Unbiased selection of the cohort? Yes
2) Selection minimizes baseline differences in
prognostic factors? Yes
3) Sample size calculated/5% difference? Yes
4) Adequate description of the cohort? Yes
5) Validated method for ascertaining exposure? Yes
6) Validated method for ascertaining clinical
outcomes? Yes
7) Outcome assessment blind to exposure? Yes
8) Adequate follow-up period? Partial; range of follow-
up for observing initiation/discontinuation events was
6-13 months
9) Completeness of follow-up? Yes
10) Analysis controls for confounding? Partial; length
of follow-up not treated as a covariate in adjusted
logistic regression models
11) Analytic methods appropriate? Yes
Funding: National Institute on Aging
Lackner et al.
(1995) [9]
To assess warfarin use
and monitoring in
nursing home
patients with NVAF,
according to
American College of
Chest Physicians
Consensus
Conference guidelines
Design:
retrospective,
cross-sectional
study
Data source:
medical record
review and
attending
physician
response to
written
communication
from the nursing
home’s medical
director and
consultant
pharmacist
Population: 902 patients
aged ≥ 60 years, from
whom 69 with a
diagnosis of NVAF and 16
with VAF (control group)
were identified
Setting: 5 nursing homes
in Minneapolis-St Paul,
Minn (US)
Time period: 1-month
period (June 1993)
NVAF was documented in 7.6% and VAF in 1.8% of
the patients. Only 17% of patients with NVAF were
receiving warfarin, compared to 31% of patients with
VAF. 58% of patients with NVAF and without a
conventional contraindication to warfarin had ≥ 1 risk
factor for thromboembolism in addition to AF and
advanced age, yet only 20% used warfarin
Quality assessment for observational studies:
1) Unbiased selection of the cohort? Yes
2) Selection minimizes baseline differences in
prognostic factors? Yes
3) Sample size calculated/5% difference? No; low
power
4) Adequate description of the cohort? Yes
5) Validated method for ascertaining exposure? Yes
6) Validated method for ascertaining clinical
outcomes?
Yes
7) Outcome assessment blind to exposure? Yes
8) Adequate follow-up period? Yes (cross-sectional)
9) Completeness of follow-up? Yes
10) Analysis controls for confounding? Partial;
evaluated univariate association of stroke risk factors
and warfarin contraindications with warfarin use
11) Analytic methods appropriate? Partial; CIs not
included in any findings
Funding: Dupont Pharmaceuticals
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3Table 1 Warfarin indications, rate of use and prescribing patterns (Continued)
Lapane et al.
(2006) [19]
To evaluate the
impact of the
implementation of
the Medicare PPS on
pharmacologic
secondary ischemic
stroke prevention
(standing orders for
antiplatelets or
warfarin) in nursing
homes
Design:
retrospective
cohort study
Data source: the
SAGE database
(including MDS
data and all drugs
taken 7 days
preceding MDS
assessment)
Population: residents who
were hospitalized with an
ischemic stroke within 6
months (1997, n = 5008;
2000, n = 5243) of living
in nursing facilities
Setting: nursing facilities
in Kansas, Maine,
Mississippi, or Ohio (1997:
n = 1226; 2000: n =
1092) (US)
Time period: Pre- PPS
period = 1997; post-PPS
period = 2000
The unadjusted proportion of use of pharmacologic
agents for the secondary prevention of stroke was
similar for warfarin in both time periods (1997: 22.9%;
2000: 22.4%) and increased for antiplatelets
(1997:40.8%; 2000: 47.7%), as a result of the
introduction of clopidogrel. Among residents with
conditions indicating the use of warfarin, after
adjusting for resident and facility characteristics, the
likelihood of use of antiplatelets increased in the post-
PPS era (adjusted OR = 1.26; 95% CI = 1.15-1.38); the
likelihood of use of the use of warfarin did not
change (adjusted OR = 0.99; 95% CI = 0.86-1.14)
Quality assessment for observational studies:
1) Unbiased selection of the cohort? Yes
2) Selection minimizes baseline differences in
prognostic factors? Partial; design does control for
effects of history other than implementation of PPS
between pre- and post-PPS period (e.g. issuance of
prescribing guidelines)
3) Sample size calculated/5%
difference? Yes
4) Adequate description of the cohort? Yes
5) Validated method for ascertaining exposure? Yes
6) Validated method for ascertaining clinical
outcomes? Yes
7) Outcome assessment blind to exposure? Yes
8) Adequate follow-up period? Partial; evaluated only
1 pre- and post-PPS year; cross-sectional
9) Completeness of follow-up? Yes
10) Analysis controls for confounding? Yes
11) Analytic methods appropriate? Yes
Funding: supported by a National Primary Care Career
Scientist Award from the Research and Development
Office, Northern Ireland
Lau et al.
(2004) [10]
To identify patterns
and predictors of
antithrombotic use
and to evaluate the
appropriateness of
antithrombotic
therapy for stroke
prophylaxis in
institutionalized
elderly patients with
AF
Design:
retrospective
cohort study
Data source:
Administrative
databases and
medical records
Population: 265 LTC
residents, aged ≥ 65 and
older, with AF
Setting: 17 LTC
institutions in Edmonton,
Alberta (Canada)
Time period: Nov 2001 -
Feb 2002
Warfarin was prescribed for 49% of patients, aspirin
for 22%, both for 8%, and neither for 20%. Nearly all
patients (97%) were considered to be at high risk for
stroke, with age being the predominant risk factor
(88% ≥ 75 years), whereas about half (54%) were
considered to be at low risk for bleeding. Multivariate
analyses found no associations between individual risk
factors for bleeding and anticoagulation treatment,
with the exception of recent surgery (OR = 0.59; 95%
CI = 0.37-0.94). Overall, 54.8% of patients received
appropriate antithrombotic therapy congruent with
stroke and bleeding. Of patients who were optimal
candidates for anticoagulation, 60% received
appropriate therapy (warfarin with or without aspirin)
Quality assessment for observational studies:
1) Unbiased selection of the cohort? Yes
2) Selection minimizes baseline differences in
prognostic factors? Yes
3) Sample size calculated/5% difference? Yes
4) Adequate description of the cohort? Yes
5) Validated method for ascertaining exposure? Partial;
unlike stroke risk, categorization by bleeding risk not
based on validated algorithm or consensus guideline
6) Validated method for ascertaining clinical
outcomes? Yes
7) Outcome assessment blind to exposure? Yes
8) Adequate follow-up period? Yes; cross-sectional
9) Completeness of follow-up? Yes
10) Analysis controls for confounding? Yes
11) Analytic methods appropriate? Yes
Funding: not specified
N
e
i
d
e
c
k
e
r
e
t
a
l
.
B
M
C
G
e
r
i
a
t
r
i
c
s
2
0
1
2
,
1
2
:
1
4
h
t
t
p
:
/
/
w
w
w
.
b
i
o
m
e
d
c
e
n
t
r
a
l
.
c
o
m
/
1
4
7
1
-
2
3
1
8
/
1
2
/
1
4
P
a
g
e
7
o
f
3
3Table 1 Warfarin indications, rate of use and prescribing patterns (Continued)
McCormick
et al. (2001)
[11]
To assess: (1) the
prevalence of AF and
the percentage of AF
patients who receive
therapy with warfarin
or aspirin, (2) the
relationship between
the presence of
known risk factors for
stroke and bleeding
among persons with
AF and their receipt
of warfarin, and (3)
the quality of warfarin
prescribing and
monitoring in nursing
home residents with
AF
Design:
retrospective
cohort study
Data source:
Medical record
review
Population: 2587 LTC
residents
Setting: 21 LTC facilities in
Connecticut (US)
Time period: 1997-1998
AF was present in 17% of LTC residents, risk factors
for stroke in 93% of AF residents, and for bleeding in
80% of AF residents. Overall, 42% of AF patients were
receiving warfarin. However, of 83 ideal candidates,
only 53% were receiving this therapy. The odds of
receiving warfarin in the study sample decreased with
increasing number of risk factors for bleeding
(adjusted OR for > 1 bleeding risk factor compared to
none: 0.51; CI, 0.29-0.94) and increased (non-
significant trend) with increasing number of stroke
risk factors
Quality assessment for observational studies:
1) Unbiased selection of the cohort? Yes
2) Selection minimizes baseline differences in
prognostic factors? Yes
3) Sample size calculated/5% difference? Yes
4) Adequate description of the cohort? Yes
5) Validated method for ascertaining exposure? No;
stroke risk and bleeding risk classification not
adequately described (i.e. no reference to validated
algorithm or consensus guideline)
6) Validated method for ascertaining clinical
outcomes? Yes
7) Outcome assessment blind to exposure? Yes
8) Adequate follow-up period? Yes; cross-sectional
9) Completeness of follow-up? Yes
10) Analysis controls for confounding? Partial; a small
list of potential confounders was included in the
logistic regression model
11) Analytic methods appropriate? Yes
Funding: Health Care Financing Administration,
Department of
Health and Human Services
Quilliam et al.
(2001) [12]
To explore
characteristics of
nursing home
residents who are
stroke survivors and
factors associated
with secondary
prevention of stroke
in nursing homes
Design:
Retrospective
cross-sectional
study
Data source: MDS
Population: 53,829 (20.4%)
residents aged > 65 years
with a diagnosis of stroke
(stroke type unknown)
Setting: all nursing home
residents in 5 states (US)
Time period: 1992-1995
67% of stroke survivors and > 50% of those
hospitalized with stroke over the previous 6 months
were not receiving drug therapy for stroke prevention.
Among those treated, most received aspirin alone
(16%) or warfarin alone (10%). Independent predictors
of drug treatment included co-morbid conditions (e.g.
hypertension, AF, depression, Alzheimer’s disease,
dementia, history of GI bleeding, and peptic ulcer
disease). Those aged ≥ 85 years were less likely to be
treated than those aged 65-74 years (OR = 0.86; 95%
CI = 0.82-0.91); black residents were less likely to be
treated than whites (OR = 0.80; 95% CI = 0.75-0.85);
and those with severe cognitive (OR = 0.63; 95% CI =
0.60-0.67) or physical impairment (OR = 0.69; 95% CI
= 0.64-0.75) were also less likely to receive drug
treatment
Quality assessment for observational studies:
1) Unbiased selection of the cohort? Yes
2) Selection minimizes baseline differences in
prognostic factors? Yes
3) Sample size calculated/5% difference? Yes
4) Adequate description of the cohort? Yes
5) Validated method for ascertaining exposure? Partial;
only a limited set of bleeding risk factors were
considered in the logistic regression model
6) Validated method for ascertaining clinical
outcomes? Yes
7) Outcome assessment blind to exposure? Yes
8) Adequate follow-up period? Yes; cross-sectional
9) Completeness of follow-up? Yes
10) Analysis controls for confounding? Yes
11) Analytic methods appropriate? Yes
Funding: National Institute on Aging, AHRQ
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3Table 1 Warfarin indications, rate of use and prescribing patterns (Continued)
Sloane et al.
(2004) [13]
To determine the
prevalence and
predictors of non-
prescribing of
selected medications
for 4 common
geriatric conditions
(including aspirin or
anticoagulants for
persons with a history
of stroke) whose
value in decreasing
morbidity has been
established in clinical
trials
Design: Cross-
sectional study
Data source:
patient
characteristics and
diagnoses were
based on medical
record reviews
and in-person
patient
assessments; data
on facility
characteristics
were obtained by
interviewing
facility
administrators
Population: 2014 residents
aged ≥ 65 years
Setting: a stratified
random sample of 193
residential care/assisted
living facilities in Florida,
Maryland, New Jersey,
and North Carolina (US)
Time period: Oct 1997 -
Nov 1998
Of 435 patients with prior stroke (stroke type not
specified) 14.4% had a contraindication for aspirin use
and 0% had a contraindication for warfarin use. 37.5%
were not receiving an anticoagulant or antiplatelet
agent. Neither bivariate nor multivariate analysis
showed an association between non-prescribing and
resident characteristics. Some facility characteristics
were associated with non-prescribing in bivariate
analysis (traditional vs small facility [OR = 0.55; P <
0.05], new model vs small facility [OR = 0.47; P <
0.01], presence of an RN/LPN [OR = 0.58; P < 0.05]).
However, in the multivariate analysis no facility
characteristics were significantly associated with Non-
prescribing
Quality assessment for observational studies:
1) Unbiased selection of the cohort? Yes
2) Selection minimizes baseline differences in
prognostic factors?
Yes
3) Sample size calculated/5% difference? Yes
4) Adequate description of the cohort? Yes
5) Validated method for ascertaining exposure? No;
contraindication to warfarin use not evaluated;
contraindication to aspirin use limited to peptic ulcer
disease
6) Validated method for ascertaining clinical
outcomes? Yes
7) Outcome assessment blind to exposure? Yes
8) Adequate follow-up period? Yes; cross-sectional
9) Completeness of follow-up? Yes
10) Analysis controls for confounding? Partial; many
covariates in multiple drug therapy study have little
relevance to warfarin or antiplatelet use
11) Analytic methods appropriate? Yes
Funding: National Institute on
Aging
Part B: Medication management interventions
Crotty et al.
(2004) [20]
To assess whether
pharmacist outreach
visits would improve
the implementation
of evidence-based
clinical practice in the
area of falls reduction
and stroke prevention
in a residential care
setting
Design:
randomized
control trial
Data source: pre-
and post-
intervention case
note audits
Population: 452 residential
care staff was surveyed;
121 physicians were
involved, with 61
receiving outreach visits.
Pre- and post-
intervention data were
available for 715 LTC
residents
Setting: 10 nursing homes
and 10 hostels (low-level
facilities) in South
Australia
Time period: 7-month
follow-up period (dates
not specified)
No statistically significant difference between groups
for numbers of patients at risk of stroke on aspirin at
follow-up. Percent of residents with AF recorded on
warfarin was similar between groups: 22.6% (pre) and
17.1% (post) in the control group, and 8.6% (pre) and
16.7% (post) in the intervention group (RR = 0.92;
95% CI = 0.23-3.95)
Quality assessment for observational studies:
1) Baseline comparability? Yes
2) Valid AD/cognitive outcomes assessment? Yes
3) Subjects/providers blind? Cannot be determined
4) Outcome assessors blind? Yes
5) Incomplete data adequately addressed? Yes
6) Differential dropout rate < 10%? Yes
7) Overall dropout rate < 30%? Yes; was 22.5% but as
high as 37% in some cluster facilities
8) Conflict of interest reported and insignificant? Yes
9) Randomization adequate? Yes
10) Allocation concealment adequate? Yes
Funding: National Health & Medical Research Council
Evidence Based Clinical Practice Research Program
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3Table 1 Warfarin indications, rate of use and prescribing patterns (Continued)
Horning et al.
(2007) [21]
To evaluate clinical
practice guideline
adherence (including
antiplatelet and
anticoagulation
therapy for secondary
stroke in prevention)
in patients LTC
facilities who received
pharmacist-directed
DSM compared with
patients in other LTC
facilities who received
traditional DRR
Design:
retrospective
cohort study
Data source: chart
review
Population: for the
secondary stroke
prevention subgroup, 18
stroke patients who
received DSM services
and 86 stroke patients
who received DRR
services
Setting: DSM services
(intervention) in 2 LTC
facilities and DRR services
(control) in 4 LTC facilities
(US)
Time period: Nov 2005
For patients with prior stroke, more DSM vs DDR
patients received aspirin, clopidogrel or warfarin or
were recognized with a contraindication (unadjusted,
88.9% vs 69.8%; P = 0.096; adjusted OR = 5.380; 95%
CI = 0.975- 29.684)
Quality assessment for observational studies:
1) Unbiased selection of the cohort? No; control
group was determined retrospectively
2) Selection minimizes baseline differences in
prognostic factors? Partial; control group was
determined by authors to be representative mix of
local usual pharmacist consultant services
3) Sample size calculated/5% difference? No;
intervention group may have lacked power due to
low n = 107 residents
4) Adequate description of the cohort? Yes
5) Validated method for ascertaining exposure? Partial;
description of DSM intervention for each of seven
diseases evaluated was limited
6) Validated method for ascertaining clinical
outcomes? Partial; description of guideline adherence
scoring limited; only cite consensual guidelines
7) Outcome assessment blind to exposure? No
8) Adequate follow-up period? Yes
9) Completeness of follow-up? Yes
10) Analysis controls for confounding? No; did not
adjust for institutional characteristics in logistic
regression models
11) Analytic methods appropriate? No; limited
covariate set unchanged among seven disease logistic
regression models; stroke and bleeding risk not
adequately modeled; no multiplicity adjustment
Funding: No outside funding.
Papaioannou
et al. (2010)
[24]
To evaluate the
MEDeINR system (an
electronic decision
support system based
on a validated
algorithm for warfarin
dosing) by examining
the impact on INR
control, testing
frequency, and
experiences of staff in
using the system
Design:
retrospective/
prospective
cohort study (pre-
post
implementation
design)
Data source: pre-
implementation:
retrospective chart
audit; post-
implementation:
central computer
database
Population: 128 residents
(without prosthetic valve)
who were taking warfarin
Setting: 6 LTC homes in
Ontario (Canada)
Time period: 6 months, 3
months prior to MEDeINR
implementation and 3
months post-
implementation (dates
not specified)
128 (10%) of all residents (excluding those with a
prosthetic valve) were taking warfarin in 6 LTC homes.
The primary indications for taking warfarin were: AF
(74%), DVT (20%), and PE (6%)
Quality assessment for observational studies:
1) Unbiased selection of the cohort? No; potential
survivor bias since residents who discontinued
warfarin prior to intervention due to poor INR control
would not have been eligible for study
2) Selection minimizes baseline differences in
prognostic factors? Partial; pre- and post-intervention
without control does not adjust for biases such as
history and maturation
3) Sample size calculated/5% difference? Yes
4) Adequate description of the cohort? Yes
5) Validated method for ascertaining exposure? Yes
6) Validated method for ascertaining clinical
outcomes? Yes
7) Outcome assessment blind to exposure? No
8) Adequate follow-up period? Partial; some residents
had < 3 months of follow-up
9) Completeness of follow-up? No; differential follow-
up in pre- and post- periods not evaluated
10) Analysis controls for confounding? Partial; no
covariates modeled since subjects served as own
controls; assumes no time-varying relevant covariates
11) Analytic methods appropriate? Partial; sensitivity
analysis to test survivor bias not performed
Funding: Canadian Institute of Health Research
ADL, activities of daily living; AF, atrial fibrillation; AHRQ, Agency for Healthcare Research and Quality; CI, confidence interval; DSM, disease state management; DRR, drug regimen review; DVT, deep vein thrombosis;
GI, gastrointestinal; INR, international normalized ratio; LTC, long-term care; LPN, licensed practical nurse; MDS, Minimum Data Set; NVAF, nonvalvular atrial fibrillation; OAC, oral anticoagulation; OR, odds ratio;
OSCAR, Online Survey Certification and Automated Record; PE, pulmonary embolism; PPS, prospective payment system; RN, registered nurse; RR, relative risk; SAGE, Systematic Assessment of Geriatric drug use via
Epidemiology; VAF, valvular atrial fibrillation
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3from 17% [9] to 57% [10], while the rate of either war-
farin or antiplatelet use ranged from 62% [13] to 80%
[10].
Rate of warfarin use among AF patients
Of the eight studies above, five (n = 10,308) [7-11]
reported rates of warfarin use among LTC residents with
AF that ranged from 17% [9] to 57%[10]. Abdel-Latif and
colleagues [7] found that 46% of 117 residents with AF in
six LTC facilities had been prescribed warfarin; 79%
received either warfarin, aspirin, or clopidogrel. In a
study of 265 LTC residents with AF in Canada from
2001-2002, Lau et al.[10] found that warfarin was pre-
scribed for 57%; among residents who were considered
optimal candidates (high risk of stroke and low risk of
bleeding according to the criteria used in this study [10]),
the warfarin prescribing rate was 60%. Using 1993 data,
Lackner et al. [9], in a study of five LTC facilities, found
that only 17% of patients with non-valvular AF received
warfarin; among residents with AF with ≥ 1 additional
risk factor for stroke (besides AF) and no contraindica-
tion to warfarin use, only 20% received warfarin [9].
Gurwitz et al. [8], using data from 1993 to 1995, found
rates of warfarin use of 32% in 413 residents with AF.
Finally, in a study of 21 LTC facilities from 1997 to 1998,
McCormick et al. [11] reported that 42% of residents
with AF received warfarin, and only 53% of ideal AF can-
didates for warfarin therapy (those having no bleeding
risk factors) received it.
Rate of warfarin use among stroke patients
Three studies measured the use of warfarin in LTC facil-
ities among stroke survivors (Table 1 Part A) [12,13,19].
Lapane et al. [19] evaluated, among stroke survivors,
whether introduction of a prospective payment system
( P P S )t h a tr e q u i r e dn u r s i n gh o m e st ob e a rt h ec o s tf o r
warfarin monitoring had shifted utilization from warfarin
to antiplatelet agents. Comparing data from 1997 and
2000, Lapane et al. [19] found that the use of warfarin for
the secondary prevention of ischemic stroke did not
change significantly following the introduction of the
PPS, from 22% in 1997 to 23% in 2000, while antiplatelet
use did increase from 41% to 48% over the same period
(likely due to the introduction of clopidogrel). Sloane et
al. [13] examined 1997-1998 data from residential care/
assisted living facilities in the United States and found
that 38% of the 435 residents with a history of stroke
(type not specified) received neither warfarin nor an anti-
platelet agent. Quilliam et al. [12] analyzed records of
53,829 survivors of stroke (either ischemic or hemorrha-
gic) in all nursing homes in five states from 1992 to 1995
(SAGE database) and found that 67% were not receiving
warfarin or any antiplatelet medication for stroke preven-
tion; among residents recently hospitalized for ischemic
stroke, 52% did not receive either of these agents.
Association of Resident and/or Facility Characteristics
with Warfarin Prescribing
Eight studies [7,8,10-13,17,18] (a subset of the studies
shown in Table 1; n = 100,879), explored the relationship
between warfarin or combined warfarin/antiplatelet
usage and resident or facility characteristics. All studies
used multivariate models to adjust for potential confoun-
ders. The direction (negative, positive, none noted [i.e.
not significant]) and strength (reported odds ratio [OR])
of reported associations within these multivariate models
are summarized in Table 2.
Previous stroke or transient ischemic attack
Among residents with AF in LTC facilities, both Abdel-
Latif et al. [7] (OR = 4.93, 95% confidence interval [CI] =
2.11-11.49 [correction provided by these authors]) and
Gurwitz et al. [8] (OR = 1.87, 95% CI = 1.20-2.91), found
a positive association between having a history of stroke
and receiving warfarin. However, Lau et al. [10] found no
significant association between “previous stroke or transi-
ent ischemic attack” and warfarin in residents with AF.
Atrial fibrillation
Both Quilliam et al. [12] (OR = 2.04, 95% CI = 1.95-2.14)
and Hughes et al. [18] (OR = 1.76, 95% CI = 1.50-2.06)
found that stroke survivors with AF were twice as likely
to receive or be initiated on warfarin or antiplatelet ther-
apy, compared with stroke survivors without AF.
Other stroke risk factors
Although both Lau et al. [10] and McCormick et al. [11]
evaluated the association between degree of overall stroke
risk and use of warfarin in LTC residents with AF, neither
study found a significant association. In one study, [12]
coronary artery disease was significantly associated (OR =
1.06, 95% CI = 1.02-1.11) with use of warfarin or antiplate-
lets among stroke survivors, but in another study [10] it
was not associated with use of warfarin in residents with
A F .W h i l et w os t u d i e sf o u n dn os i g n i f i c a n ta s s o c i a t i o n
between hypertension and use of warfarin in residents
with AF [7,10], two other studies found that in stroke sur-
vivors hypertension was positively associated with initia-
tion [18] (OR = 1.23, 95% CI = 1.09-1.39) and use [12]
(OR = 1.27, 95% CI = 1.22-1.32) of warfarin or
antiplatelets.
Depression
Both Hughes et al. [18] (OR = 1.22, 95% CI = 1.02-1.46)
and Quilliam et al. [12] (OR = 1.11, 95% CI = 1.05-1.18)
found that stroke survivors with depression were more
likely to initiate or receive warfarin or antiplatelet therapy.
Age
Both Gurwitz et al. [8], studying residents with AF (OR =
0.46, 95% CI = 0.22-0.94), and Quilliam et al. [12], study-
ing stroke survivors (OR = 0.86, 95% CI = 0.82-0.91),
found that residents ≥ 85 years were less likely to be pre-
scribed either warfarin [8] or warfarin or antiplatelets [12].
Neidecker et al. BMC Geriatrics 2012, 12:14
http://www.biomedcentral.com/1471-2318/12/14
Page 11 of 33Table 2 Association of factors with warfarin prescribing
Category Factor Direction of association
(at 95% confidence)
0 = none + = positive - =
negative
Association (multivariate
adjusted) (OR, 95% CI)
Endpoint Study Condition Study
Admission Admitted from hospital + OR = 1.16
(1.02-1.31)
discontinue warfarin or antiplatelets Previous stroke Hughes et al.
(2004) [18]
0 OR = 1.12
(0.97-1.29)
initiate warfarin or antiplatelets Previous stroke Hughes et al.
(2004) [18]
Age 65-74 0 OR = 0.98
(0.61-1.57)
use of warfarin AF Lau et al.
(2004) [10]
75-84 0 OR = 0.98
(0.61-1.58)
use of warfarin AF Lau et al.
(2004) [10]
0 OR = 1.13
(0.98-1.31)
discontinue warfarin or antiplatelets Previous stroke Hughes et al.
(2004) [18]
0 OR = 0.99
(0.94-1.04)
use of warfarin or antiplatelets Previous stroke Quilliam et al.
(2001) [12]
0 not reported use of warfarin AF Gurwitz et al.
(1997) [8]
0 OR = 1.01
(0.86-1.19)
initiate warfarin or antiplatelets Previous stroke Hughes et al.
(2004) [18]
≥ 85 0 OR = 1.13
(0.70-1.82)
use of warfarin AF Lau et al.
(2004) [10]
0 OR = 1.07
(CI not reported)
use of warfarin or antiplatelets Previous stroke Sloane et al.
(2004) [13]
+ OR = 1.23
(1.05-1.43)
discontinue warfarin or antiplatelets Previous stroke Hughes et al.
(2004) [18]
- OR = 0.46
(0.22-0.94)
use of warfarin AF Gurwitz et al.
(1997) [8]
- OR = 0.86
(0.82-0.91)
use of warfarin or antiplatelets Previous stroke Quilliam et al.
(2001) [12]
0 OR = 0.86
(0.72-1.04)
initiate warfarin or antiplatelets Previous stroke Hughes et al.
(2004) [18]
Bleeding risk 1 risk factor 0 OR = 0.75
(0.41-1.36)
use of warfarin AF McCormick et
al. (2001) [11]
≥ 2 risk factors - OR = 0.51
(0.29-0.94)
use of warfarin AF McCormick et
al. (2001) [11]
High risk 0 OR = 0.82
(0.52-1.30)
use of warfarin AF Lau et al.
(2004) [10]
Cognitive
impairment
Moderate - OR = 0.93
(0.88-0.97)
use of warfarin or antiplatelets Previous stroke Quilliam et al.
(2001) [12]
0 OR = 0.93
(0.81-1.08)
initiate warfarin or antiplatelets Previous stroke Hughes et al.
(2004) [18]
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3Table 2 Association of factors with warfarin prescribing (Continued)
0 OR = 0.98
(0.86-1.12)
discontinue warfarin or antiplatelets Previous stroke Hughes et al.
(2004) [18]
Severe 0 OR = 1.19
(0.99-1.44)
discontinue warfarin or antiplatelets Previous stroke Hughes et al.
(2004) [18]
- OR = 0.64
(0.52-0.80)
initiate warfarin or antiplatelets Previous stroke Hughes et al.
(2004) [18]
- OR = 0.63
(0.60-0.67)
use of warfarin or antiplatelets Previous stroke Quilliam et al.
(2001) [12]
0 OR = 1.02
(CI not reported)
use of warfarin or antiplatelets Previous stroke Sloane et al.
(2004) [13]
Conditions Active malignancy 0 OR = 0.93
(0.57-1.51)
use of warfarin AF Lau et al.
(2004)[10]
Alzheimer’s disease - OR = 0.77
(0.70-0.85)
use of warfarin or antiplatelets Previous stroke Quilliam et al.
(2001) [12]
Anemia 0 OR = 0.87
(0.55-1.39)
use of warfarin AF Lau et al.
(2004) [10]
Aneurysms 0 OR = 0.88
(0.55-1.40)
use of warfarin AF Lau et al.
(2004) [10]
Atrial fibrillation - OR = 0.73
(0.64-0.83)
discontinue warfarin or antiplatelets Previous stroke Hughes et al.
(2004) [18]
+ OR = 1.76
(1.50-2.06)
initiate warfarin or antiplatelets Previous stroke Hughes et al.
(2004) [18]
+ OR = 2.04
(1.95-2.14)
use of warfarin or antiplatelets Previous stroke Quilliam et al.
(2001) [12]
Congestive heart failure 0 OR = 1.13
(0.98-1.30)
discontinue warfarin or antiplatelets Previous stroke Hughes et al.
(2004) [18]
0 OR = 1.04
(0.65-1.65)
use of warfarin AF Lau et al.
(2004) [10]
0 not reported use of warfarin AF Abdel-Latif et
al. (2005) [7]
0 OR = 1.02
(0.87-1.20)
initiate warfarin or antiplatelets Previous stroke Hughes et al.
(2004) [18]
Coronary artery disease + OR = 1.06
(1.02-1.11)
use of warfarin or antiplatelets Previous stroke Quilliam et al.
(2001) [12]
0 OR = 0.99
(0.62-1.58)
use of warfarin AF Lau et al.
(2004) [10]
Dementia - OR = 0.84
(0.80-0.88)
use of warfarin or antiplatelets Previous stroke Quilliam et al.
(2001) [12]
- OR = 0.59
(0.38-0.90)
use of warfarin AF Gurwitz et al.
(1997) [8]
Depression + OR = 1.22
(1.02-1.46)
initiate warfarin or antiplatelets Previous stroke Hughes et al.
(2004) [18]
N
e
i
d
e
c
k
e
r
e
t
a
l
.
B
M
C
G
e
r
i
a
t
r
i
c
s
2
0
1
2
,
1
2
:
1
4
h
t
t
p
:
/
/
w
w
w
.
b
i
o
m
e
d
c
e
n
t
r
a
l
.
c
o
m
/
1
4
7
1
-
2
3
1
8
/
1
2
/
1
4
P
a
g
e
1
3
o
f
3
3Table 2 Association of factors with warfarin prescribing (Continued)
+ OR = 1.11
(1.05-1.18)
use of warfarin or antiplatelets Previous stroke Quilliam et al.
(2001) [12]
0 OR = 1.08
(0.93-1.24)
discontinue warfarin or antiplatelets Previous stroke Hughes et al.
(2004) [18]
Diabetes mellitus 0 not reported use of warfarin AF Abdel-Latif et
al. (2005) [7]
0 OR = 1.17
(0.73-1.86)
use of warfarin AF Lau et al.
(2004) [10]
Hypertension - OR = 0.87
(0.78-0.97)
discontinue warfarin or antiplatelets Previous stroke Hughes et al.
(2004) [18]
+ OR = 1.23
(1.09-1.39)
initiate warfarin or antiplatelets Previous stroke Hughes et al.
(2004) [18]
0 OR = 1.10
(0.69-1.75)
use of warfarin AF Lau et al.
(2004) [10]
0 not reported use of warfarin AF Abdel-Latif et
al. (2005) [7]
+ OR = 1.27
(1.22-1.32)
use of warfarin or antiplatelets Previous stroke Quilliam et al.
(2001) [12]
Left ventricular dysfunction 0 OR = 0.83
(0.63-1.09)
initiate warfarin or antiplatelets Previous stroke Hughes et al.
(2004) [18]
0 OR = 1.07
(0.88-1.30)
discontinue warfarin or antiplatelets Previous stroke Hughes et al.
(2004) [18]
Liver disease 0 OR = 1.53
(0.95-2.49)
use of warfarin AF Lau et al.
(2004) [10]
Major comorbidity burden 0 not reported use of warfarin AF Gurwitz et al.
(1997) [8]
Moderate comorbidity
burden
0 not reported use of warfarin AF Gurwitz et al.
(1997) [8]
Multiple conditions (4 or
more)
0 OR = 0.84
(CI not reported)
use of warfarin or antiplatelets Previous stroke Sloane et al.
(2004) [13]
Peptic ulcer disease 0 OR = 0.90
(0.57-1.43)
use of warfarin AF Lau et al.
(2004) [10]
- OR = 0.64
(0.58-0.71)
use of warfarin or antiplatelets Previous stroke Quilliam et al.
(2001) [12]
Peripheral vascular disease + OR = 1.13
(1.05-1.20)
use of warfarin or antiplatelets Previous stroke Quilliam et al.
(2001) [12]
Previous bleeding 0 not reported use of warfarin AF Gurwitz et al.
(1997) [8]
Previous falls 0 not reported use of warfarin AF Gurwitz et al.
(1997) [8]
Previous GI bleeding - OR = 0.57
(0.52-0.62)
use of warfarin or antiplatelets Previous stroke Quilliam et al.
(2001) [12]
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3Table 2 Association of factors with warfarin prescribing (Continued)
- OR = 0.18
(0.03-0.91)
use of warfarin AF Abdel-Latif et
al. (2005) [7]
Previous major bleeding 0 OR = 0.73
(0.46-1.15)
use of warfarin AF Lau et al.
(2004) [10]
Previous stroke + OR = 4.93
(2.11-11.49)
use of warfarin AF Abdel-Latif et
al. (2005) [7]
+ OR = 1.87
(1.20-2.91)
use of warfarin AF Gurwitz et al.
(1997) [8]
Previous stroke or TIA 0 OR = 1.24
(0.78-1.97)
use of warfarin AF Lau et al.
(2004) [10]
Previous systemic embolus 0 OR = 1.46
(0.92-2.34)
use of warfarin AF Lau et al.
(2004) [10]
Recent surgery - OR = 0.59
(0.37-0.94)
use of warfarin AF Lau et al.
(2004) [10]
Renal insufficiency 0 OR = 0.91
(0.57-1.45)
use of warfarin AF Lau et al.
(2004) [10]
Rheumatic mitral valvular 0 OR = 0.80
(0.50-1.28)
use of warfarin AF Lau et al.
(2004) [10]
Seizure disorder 0 OR = 1.05
(0.66-1.67)
use of warfarin AF Lau et al.
(2004) [10]
Transient ischemic attack + OR = 1.34
(1.09-1.64)
initiate warfarin or antiplatelets Previous stroke Hughes et al.
(2004) [18]
0 OR = 0.99
(0.84-1.17)
discontinue warfarin or antiplatelets Previous stroke Hughes et al.
(2004) [18]
Drug
Interaction
Uses meds that increase
bleeding risk
0 not reported use of warfarin AF Gurwitz et al.
(1997) [8]
0 OR = 1.26
(0.80-1.98)
use of warfarin AF Lau et al.
(2004) [10]
Duration of
AF
12-24 months 0 not reported use of warfarin AF Gurwitz et al.
(1997) [8]
> 24 months 0 not reported use of warfarin AF Gurwitz et al.
(1997) [8]
Onset of AF after admission 0 not reported use of warfarin AF Gurwitz et al.
(1997) [8]
Facility Alzheimer’s unit 0 OR = 0.78
(0.57-1.05)
discontinue warfarin or antiplatelets Previous stroke Hughes et al.
(2004) [18]
0 OR = 1.14
(0.80-1.62)
initiate warfarin or antiplatelets Previous stroke Hughes et al.
(2004) [18]
Hospital based 0 OR = 0.96
(0.72-1.29)
initiate warfarin or antiplatelets Previous stroke Hughes et al.
(2004) [18]
0 OR = 0.96
(0.75-1.23)
discontinue warfarin or antiplatelets Previous stroke Hughes et al.
(2004) [18]
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3Table 2 Association of factors with warfarin prescribing (Continued)
Location rural 0 OR = 0.89
(CI not reported)
use of warfarin or antiplatelets Previous stroke Sloane et al.
(2004) [13]
Location urban + OR = 1.38
(1.16-1.65)
discontinue warfarin or antiplatelets Previous stroke Hughes et al.
(2004) [18]
0 OR = 1.06
(0.87-1.3)
initiate warfarin or antiplatelets Previous stroke Hughes et al.
(2004) [18]
Large new model facility (vs
small)
0 OR = 0.61
(CI not reported)
use of warfarin or antiplatelets Previous stroke Sloane et al.
(2004) [13]
Non-white > 10% (vs > 0%
to < 5%)
0 OR = 1.09
(0.91-1.32)
initiate warfarin or antiplatelets Previous stroke Hughes et al.
(2004) [18]
+ OR = 1.22
(1.03-1.43)
discontinue warfarin or antiplatelets Previous stroke Hughes et al.
(2004) [18]
Non-white > 5% to < 10%
(vs > 0% to < 5%)
0 OR = 1.00
(0.81-1.24)
initiate warfarin or antiplatelets Previous stroke Hughes et al.
(2004) [18]
0 OR = 0.95
(0.78-1.15)
discontinue warfarin or antiplatelets Previous stroke Hughes et al.
(2004) [18]
Non-white 0% (vs > 0% to <
5%)
- OR = 0.74
(0.57-0.96)
initiate warfarin or antiplatelets Previous stroke Hughes et al.
(2004) [18]
0 OR = 1.17
(0.93-1.46)
discontinue warfarin or antiplatelets Previous stroke Hughes et al.
(2004) [18]
Ownership status for profit
(vs non-profit)
0 OR = 0.90
(0.76-1.07)
initiate warfarin or antiplatelets Previous stroke Hughes et al.
(2004) [18]
0 OR = 0.90
(0.77-1.05)
discontinue warfarin or antiplatelets Previous stroke Hughes et al.
(2004) [18]
Ownership status
government (vs non-profit)
0 OR = 0.86
(0.64-1.17)
initiate warfarin or antiplatelets Previous stroke Hughes et al.
(2004) [18]
0 OR = 0.99
(0.76-1.29)
discontinue warfarin or antiplatelets Previous stroke Hughes et al.
(2004) [18]
Part of a chain + OR = 1.20
(1.01-1.42)
initiate warfarin or antiplatelets Previous stroke Hughes et al.
(2004) [18]
- OR = 0.85
(0.73-0.99)
discontinue warfarin or antiplatelets Previous stroke Hughes et al.
(2004) [18]
Payment source % Medicaid
(per 10 unit increase)
0 OR = 0.98
(0.91-1.05)
discontinue warfarin or antiplatelets Previous stroke Hughes et al.
(2004) [18]
0 OR = 0.95
(0.88-1.03)
initiate warfarin or antiplatelets Previous stroke Hughes et al.
(2004) [18]
Payment source % other-pay
(per 10 unit increase)
0 OR = 0.94
(0.87-1.01)
discontinue warfarin or antiplatelets Previous stroke Hughes et al.
(2004) [18]
0 OR = 0.97
(0.89-1.05)
initiate warfarin or antiplatelets Previous stroke Hughes et al.
(2004) [18]
Presence of a RN/LPN 0 OR = 0.74
(CI not reported)
use of warfarin or antiplatelets Previous stroke Sloane et al.
(2004) [13]
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3Table 2 Association of factors with warfarin prescribing (Continued)
Size ≤ 80 (vs 81-199) 0 OR = 1.01
(0.81-1.26)
initiate warfarin or antiplatelets Previous stroke Hughes et al.
(2004) [18]
0 OR = 0.92
(0.77-1.11)
discontinue warfarin or antiplatelets Previous stroke Hughes et al.
(2004) [18]
Size ≥ 200 (vs 81 to 199) 0 OR = 1.17
(0.99-1.39)
discontinue warfarin or antiplatelets Previous stroke Hughes et al.
(2004) [18]
0 OR = 1.08
(0.90-1.30)
initiate warfarin or antiplatelets Previous stroke Hughes et al.
(2004) [18]
Special care unit 0 OR = 1.15
(0.83-1.59)
initiate warfarin or antiplatelets Previous stroke Hughes et al.
(2004) [18]
+ OR = 1.33
(1.02-1.73)
discontinue warfarin or antiplatelets Previous stroke Hughes et al.
(2004) [18]
Staff resources any full-time
physicians
- OR = 0.76
(0.63-0.92)
initiate warfarin or antiplatelets Previous stroke Hughes et al.
(2004) [18]
0 OR = 1.05
(0.89-1.24)
discontinue warfarin or antiplatelets Previous stroke Hughes et al.
(2004) [18]
Staff resources (contract) 0 OR = 1.04
(0.89-1.20)
initiate warfarin or antiplatelets Previous stroke Hughes et al.
(2004) [18]
0 OR = 1.02
(0.89-1.17)
discontinue warfarin or antiplatelets Previous stroke Hughes et al.
(2004) [18]
Staff resources (physician
extenders)
+ OR = 1.21
(1.0-1.47)
discontinue warfarin
or antiplatelets
Previous stroke Hughes et al.
(2004) [18]
0 OR = 1.08
(0.87-1.34)
initiate warfarin or antiplatelets Previous stroke Hughes et al.
(2004) [18]
Traditional facility (vs small) 0 OR = 0.78
(CI not reported)
use of warfarin or antiplatelets Previous stroke Sloane et al.
(2004) [13]
Weekly physician visits 0 OR = 0.94
(CI notreported)
use of warfarin or antiplatelets Previous stroke Sloane et al.
(2004) [13]
Gender Female 0 not reported use of warfarin AF Gurwitz et al.
(1997) [8]
- OR = 0.94
(0.90-0.98)
use of warfarin orantiplatelets Previous stroke Quilliam et al.
(2001) [12]
0 OR = 0.99
(0.87-1.13)
initiate warfarin orantiplatelets Previous stroke Hughes et al.
(2004) [18]
0 OR = 1.00
(0.89-1.13)
discontinue warfarinor antiplatelets Previous stroke Hughes et al.
(2004) [18]
0 OR = 0.81
(CI not reported)
use of warfarin orantiplatelets Previous stroke Sloane et al.
(2004) [13]
Physical
Function
Substantial mobility 0 not reported use of warfarin AF Gurwitz et al.
(1997) [8]
Mild impairment 0 not reported use of warfarin AF Gurwitz et al.
(1997) [8]
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3Table 2 Association of factors with warfarin prescribing (Continued)
Intermediate mobility 0 not reported use of warfarin AF Gurwitz et al.
(1997) [8]
Moderate impairment 0 OR = 0.95
(0.75-1.20)
discontinue warfarin or antiplatelets Previous stroke Hughes et al.
(2004) [18]
0 OR = 0.90
(0.70-1.16)
initiate warfarin or antiplatelets Previous stroke Hughes et al.
(2004) [18]
0 not reported use of warfarin AF Gurwitz et al.
(1997) [8]
0 OR = 1.03
(0.95-1.11)
use of warfarin or antiplatelets Previous stroke Quilliam et al.
(2001) [12]
Dependent - OR = 0.69
(0.64-0.75)
use of warfarin or antiplatelets Previous stroke Quilliam et al.
(2001) [12]
- OR = 0.73
(0.56-0.96)
initiate warfarin or
antiplatelets
Previous stroke Hughes et al.
(2004) [18]
0 OR = 0.99
(0.79-1.25)
discontinue warfarin or antiplatelets Previous stroke Hughes et al.
(2004) [18]
0 OR = 1.21
(CI notreported)
use of warfarin or antiplatelets Previous stroke Sloane et al.
(2004) [13]
Severe impairment 0 not reported use of warfarin AF Gurwitz et al.
(1997) [8]
Race/
ethnicity
American Indian 0 OR = 1.00
(0.70-1.43)
discontinue warfarin or antiplatelets Previous stroke Hughes et al.
(2004) [18]
0 Difference = -0.8(-8.9 to 7.3) prevalence difference from non-Hispanic white
for receiving warfarin or antiplatelets
Recent ischemic
stroke
Christian et al.
(2003) [17]
0 OR = 1.47
(0.98-2.20)
initiate warfarin or antiplatelets Previous stroke Hughes et al.
(2004) [18]
Asian/Pacific islander 0 Difference = -5.2
(-18.1 to 7.8)
prevalencedifference from non-Hispanic white for
receiving warfarin or antiplatelets
Recentischemicstroke Christian et al.
(2003) [17]
0 OR = 0.71
(0.42-1.21)
initiate warfarin or antiplatelets Previous stroke Hughes et al.
(2004) [18]
- OR = 0.44
(0.23-0.83)
discontinue warfarin or antiplatelets Previous stroke Hughes et al.
(2004) [18]
Black - OR = 0.80
(0.75-0.85)
use of warfarin or antiplatelets Previous stroke Quilliam et al.
(2001) [12]
Hispanic 0 Difference = - 7.6
(-17.6 to 2.2)
prevalence difference from non-Hispanic white
for receiving warfarin or antiplatelets
Recent
ischemic
stroke
Christian et al.
(2003) [17]
0 OR = 0.81
(0.51-1.29)
initiate warfarin or antiplatelets Previous
stroke
Hughes et al.
(2004) [18]
0 OR = 1.01
(0.62-1.65)
discontinue warfarin or antiplatelets Previous stroke Hughes et al.
(2004) [18]
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3Table 2 Association of factors with warfarin prescribing (Continued)
Non- Hispanic black - OR = 0.62
(0.49-0.78)
initiate warfarin or antiplatelets Previous stroke Hughes et al.
(2004) [18]
0 OR = 1.03
(0.86-1.24)
discontinue warfarin or antiplatelets Previous stroke Hughes et al.
(2004) [18]
- Difference = - 7.6
(-11.2 to -3.9)
prevalence difference from non-Hispanic white
for receiving warfarin or antiplatelets
Recent ischemic
stroke
Christian et al.
(2003) [17]
Other 0 OR = 0.95
(0.86-1.04)
use of warfarin or antiplatelets Previous stroke Quilliam et al.
(2001) [12]
White 0 OR = 0.69
(CI not reported)
use of warfarin or antiplatelets Previous stroke Sloane et al.
(2004) [13]
Stroke risk 1 risk factor 0 OR = 1.44
(0.52-4.03)
use of warfarin AF McCormick et
al. (2001) [11]
2 risk factors 0 OR = 2.44
(0.93-6.39)
use of warfarin AF McCormick et
al. (2001) [11]
3 risk factors 0 OR = 2.37
(0.90-6.20)
use of warfarin AF McCormick et
al. (2001) [11]
≥ 4 risk factors 0 OR = 2.50
(0.90-6.95)
use of warfarin AF McCormick et
al. (2001) [11]
High risk 0 OR = 1.49
(0.93-2.36)
use of warfarin AF Lau et al.
(2004)[10]
AF, atrial fibrillation; CI, confidence interval; OR, odds ratio
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3However studies of residents with AF [10] and stroke sur-
vivors [13,18], respectively, found no significant correla-
tion between age ≥ 85 years and use of these agents.
Hughes et al. [18] evaluated stroke survivors in their first
year after nursing home admission: residents ≥ 85 years
were most likely to discontinue warfarin or antiplatelet
therapy (OR = 1.23, 95% CI = 1.05-1.43).
Dementia and severe cognitive impairment
Gurwitz et al. [8] reported that AF residents with demen-
tia were less likely than those without it to receive war-
farin therapy (OR = 0.59, 95% CI = 0.38-0.90). Quilliam
et al. [12] further found that among residents who were
stroke survivors, those with Alzheimer’sd i s e a s e( O R=
0.77, 95% CI = 0.70-0.85) or dementia (OR = 0.84, 95%
CI = 0.80-0.88) were less likely to receive warfarin or
antiplatelets; the likelihood of anticoagulant or antiplate-
let therapy also decreased among residents with moder-
ate (OR = 0.93, 95% CI = 0.88-0.97) or severe (OR = 0.63,
95% CI = 0.60-0.67) cognitive impairment [12]. Hughes
et al. [18] also found that stroke survivors with severe
cognitive impairment were less likely to initiate such
therapy (OR = 0.64, 95% CI = 0.52-0.80). In contrast,
Sloane et al. [13] found no significant association
between severe cognitive impairment and use of warfarin
or antiplatelets in stroke survivors.
Physical functioning
Both Quilliam et al. [12] (OR = 0.69, 95% CI = 0.64-0.75)
and Hughes et al. [18] (OR = 0.73, 95% CI = 0.56-0.96)
found that stroke survivors who had dependent physical
function were less likely to receive warfarin or antiplate-
lets than those with independent function. However,
Sloane et al. [13] found no significant association
between physical dependency and receiving these agents
among stroke survivors, and Gurwitz et al. [8] found no
significant association between severe physical impair-
ment and the use of warfarin in LTC residents with AF.
Bleeding risk factors
Abdel Latif et al. [7] found a negative association (OR =
0.18, 95% CI = 0.03-0.91) between previous gastrointest-
inal (GI) bleed and warfarin use in residents with AF.
Quilliam et al. [12] also found a negative relationship
(OR = 0.57, 95% CI = 0.52-0.62) between GI bleeding
and warfarin or antiplatelet use in stroke survivors. In
that study, Quilliam et al. [12] also found a negative asso-
ciation (OR = 0.64, 95% CI = 0.58-0.71) between peptic
ulcer disease and these agents, although Lau et al. [10]
found no significant association between peptic ulcer dis-
ease and warfarin use in AF. Evaluating bleeding risk fac-
tors among AF residents, Lau et al. [10] observed no
significant association between warfarin treatment and
overall bleeding risk or any single risk factor for bleeding,
with the exception of recent surgery. However, McCor-
mick et al. [11] reported that the odds of warfarin
treatment were significantly lower (OR = 0.51, 95% CI =
0.29-0.94) for residents with AF and ≥ 2 bleeding risk
factors.
Race/ethnicity
Among residents with a history of stroke, four studies
noted an association between race/ethnicity and being pre-
scribed warfarin or antiplatelet therapy. Christian et al.
[17] found that non-Hispanic blacks with a recent hospita-
lization for ischemic stroke and an indication for warfarin
received warfarin less often (7.6% lower rate) than non-
Hispanic white residents. In a study by Hughes et al. [18],
in the year after nursing home admission, non-Hispanic
black stroke survivors were less likely than non-Hispanic
whites (OR = 0.62, 95% CI = 0.49-0.78) to be initiated on
warfarin or antiplatelet therapy. Quilliam et al. [12] found
that black stroke survivors were less likely than whites
(OR = 0.80, 95% CI = 0.75-0.85) to receive warfarin or any
antiplatelets. Although Abdel-Latif et al. [7] reported that
non-Caucasian stroke survivors with AF were less likely
than Caucasians to be prescribed warfarin therapy, these
findings appear to be bivariate and were not significant in
their multivariate model (OR was not reported).
LTC facility
For residents within residential care/assisted living facil-
ities, Sloane et al. [13] explored the association between
resident and facility characteristics and warfarin or anti-
platelet prescribing for stroke survivors. Although bivari-
ate analysis found that several facility characteristics,
including larger facilities and those with registered nurses
or licensed practical nurses, were associated with non-
prescribing, multivariate analysis found no independent
association for resident or facility characteristics. After
adjusting for facility and resident characteristics, Hughes
et al. [18] found that LTC facilities with white-only resi-
dents (OR = 0.74, 95% CI = NA) or the presence of full-
time physicians (OR = 0.76, 95% CI = 0.63-0.93) were
less likely, and that those that were part of a chain (OR =
1.20, 95% CI = 1.01-1.42), were more likely, to initiate
warfarin or antiplatelets in stroke survivors. Moreover,
facilities with > 10% non-white residents (OR = 1.22, 95%
CI = 1.03-1.43), in an urban location (OR = 1.38, 95%
CI = 1.16-1.65), having physician extenders on staff
(OR = 1.21, 95% CI = 1.0-1.47), or having special care
units (OR = 1.33, 95% CI = 1.02-1.73) were more likely
to discontinue active warfarin or antiplatelet therapy.
Quality assessment
Quality assessment ratings are listed for each of the 14
studies in Table 1. Methodological quality of each study
was adequate for all but four areas. One or more limita-
tions or concerns were noted for nine studies
[7,9,11,13,17,18,21,24,25]. These included failing to ade-
quately account for potential confounders, failing to con-
sistently describe statistical error for the point estimates
Neidecker et al. BMC Geriatrics 2012, 12:14
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Page 20 of 33reported or to adequately model the relationship between
stroke and bleeding risk with warfarin use. In the last
case, typical problems noted were either omitting risk
factors or else failing to score risks using a validated scor-
ing method or consensus guidelines. Four studies
[7,9,17,21] had small sample sizes: subject counts for
these studies would not have been able to support a find-
ing of 95% significance for an OR of 1.5. Four studies
[17-19,24] had limitations in length of follow-up.
Prescriber Attitudes and Concerns about Warfarin Use
Two studies (n = 289) [27,29] explored physician atti-
tudes toward warfarin prescribing using case-study ques-
tionnaires targeted to physicians (Table 3), while one
study (n = 91) [28] (Table 3) explored physician attitudes
regarding specialized warfarin services. Dharmarajan
et al. [27] evaluated respondent decisions regarding the
use of warfarin therapy in the hypothetical case of a
white 87-year-old female LTC resident with a history of
Alzheimer’s disease, surgery for a hip fracture, and AF.
The resident, who was wheelchair-bound and dependent
for most activities of daily living, had swelling on her
forehead from a recent fall, but was negative for fracture
on radiological examination. A large majority of respond-
ing physicians (85%) believed that long-term warfarin
therapy was not indicated for this patient. However, most
(88%) said they would prescribe an antiplatelet agent.
The reasons most commonly cited for not prescribing
warfarin were risk of falls (98%), dementia (40%), and
limited life expectancy (32%).
In a similar study, Monette et al. [29] used two case
studies - a 94-year old male with chronic AF and co-mor-
bid CHF but having independent physical function and
no fall history, and an 80-year old female stroke survivor
with AF and CHF who also had hemiplegia, dysarthria,
and a recent fall history–to assess physicians’ knowledge
and attitudes regarding the use of warfarin for stroke pre-
vention in residents with AF. Only 47% of respondents
believed that the benefits of warfarin therapy greatly out-
weighed the risks in this setting; the remainder indicated
that benefits outweighed the risks only slightly (34%) or
that the risks outweighed the benefits (19%). Contraindi-
cations to warfarin use that were cited most frequently
included excessive risk of falls (71%), history of GI bleed-
ing (71%), history of other non-central nervous system
(CNS) bleeding (36%), and history of cerebrovascular
hemorrhage (25%) [29]. Geriatricians were significantly
more likely than other physicians to recommend warfarin
in the older but more functional case-study resident.
Harrold et al. [28] explored physician attitudes regarding
the use of specialized warfarin services in the LTC setting.
The majority of physicians agreed that a warfarin service
could reduce the workload on physicians and increase the
percent of time that residents receiving warfarin are
maintained in the target therapeutic range. However, most
physicians did not believe that such a service would reduce
the risk of warfarin-related bleeding. Only about half of
respondents indicated that they might use a warfarin ser-
vice for managing their residents on warfarin.
Quality assessment
Although the three physician surveys described above
were innovative, their methodological quality was some-
what low in critical areas. While all three studies intro-
duced new self-administered questionnaires, only one
analyzed data regarding non-responders [28], while two
[27,28] did not mention steps taken to develop content
validity. None of the surveys provided details regarding
analysis of item response for the purpose of assessing
construct validity. Finally, all three studies had limitations
with analysis: failure either to adequately report statistical
error or to cross-tabulate responses with subject
attributes.
Warfarin Management and Monitoring
International normalized ratio (INR)
The quality of warfarin management and monitoring
(Table 4 Part A) was measured in seven studies (n =
10,718) [8,9,11,22,25,30,31], six of which (n = 10,681)
[8,9,11,22,25,30] evaluated the percentage of time or per-
son-days spent by residents in therapeutic range, based
on INR results. In these six studies, INR levels were in
t h et a r g e tr a n g e( 2 . 0 - 3 . 0 )f o ram e a n4 8 %o ft h et i m e
(range = 37-55%). Four of these studies [8,11,22,25] also
reported percentage of time or person-days in subthera-
peutic or supratherapeutic ranges. INR levels were in the
subtherapeutic range (< 2.0) for a mean of 38% of the
time (range = 35-45%) and in the supratherapeutic range
(> 3.0) for a mean of 14% of the time (range = 11-16%).
One study, Karki et al. [31], reported only mean INRs for
residents and only for those whose INR values indicated
either adequate or poor INR control.
Two studies that evaluated the effectiveness of warfarin
medication management systems [23,24] (n = 175, Table 4
Part B) found post-interventional time in therapeutic
range considerably higher than reported in the six studies
above. Papaioannou et al. [24] studied the effects of an
electronic decision-support system for warfarin dosing and
found that time in therapeutic range was 65% (pre-inter-
vention) to 69% (post-intervention; the post-interventional
change was non-significant). In a study of warfarin man-
agement by nurse practitioners, Allen et al. [23] measured
85% of INR draws within therapeutic range. These mea-
surements were post-intervention only; no pre-interven-
tion or control results were reported.
Factors associated with INR range
Three studies [22,30,31] (Table 4 Part A) evaluated the
association of resident characteristics with INR (n =
302). Aspinall et al. [30] noted that residents who began
Neidecker et al. BMC Geriatrics 2012, 12:14
http://www.biomedcentral.com/1471-2318/12/14
Page 21 of 33Table 3 Prescriber attitudes and concerns with warfarin use
Study Study objective, (intervention/
exposure and outcomes)
Study design, data source Study population, study setting,
time period
Results Quality assessment,
funding source
Dharmarajan
et al. (2006)
[27]
To evaluate the decision whether or
not to anticoagulate among
physicians in practice and in various
levels of training (residents and
fellows) for a specific, yet not
unusual, case scenario in the nursing
home
Design: cross-sectional study
Data source: survey questionnaire
based on an actual case from an LTC
facility. The subject of the survey was
an 87-year-old female LTC facility
resident with dementia, AF, and
history of hip fracture who suffered a
recent fall without fracture
Population: 107 completed surveys
were returned from 49 residents, 20
fellows, and 38 attending
physicians
Setting: a university teaching
hospital in the Bronx, NY (US)
Time period: survey dates not
specified
The majority of physicians (85%)
thought that long-term
anticoagulation therapy was not
indicated in the case patient.
However, most (88%) said they
would provide an antiplatelet agent
(78% aspirin, 20% clopidogrel). The
most cited reasons for not providing
anticoagulation were risk of falls
(98%), dementia (40%), and short life
expectancy (32%). 92% of
respondents said the patient was a
candidate for short-term
anticoagulation therapy. Responses
to the questions were similar for all
physicians (or faculty) irrespective of
level of training or years in practice
Quality assessment for
observational studies:
1) Unbiased selection of
the cohort? Cannot be
determined; cohort
selection details not
provided; non-response
rate not disclosed
2) Selection minimizes
baseline differences in
prognostic factors? Cannot
be determined
3) Sample size calculated/
5% difference? No
4) Adequate description of
the cohort? No; details of
cohort other than practice
specialty were not
provided
5) Validated method for
ascertaining exposure? No;
reliability concern since
limited to 1 case study;
content validity of case
study not described
6) Validated method for
ascertaining clinical
outcomes? No; validation
assessment of response
choices not performed
7) Outcome assessment
blind to exposure? NA
8) Adequate follow-up
period? Yes; cross-sectional
9) Completeness of follow-
up? Yes
10) Analysis controls for
confounding? Partial; cross-
tabulations performed on
responses by specialty
11) Analytic methods
appropriate? Yes
Funding: Geriatric
Medicine Fellowship
program
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3Table 3 Prescriber attitudes and concerns with warfarin use (Continued)
Harrold et al.
(2002) [28]
To examine physician attitudes
regarding the use of specialized
anticoagulation services in the LTC
setting
Design: cross-sectional study
Data source: survey questionnaire
Population: 245 physicians asked to
participate in the survey; 114 (47%)
responded. 91 reported that they
currently cared for residents in LTC
facilities and thus completed the
questionnaire
Setting: 21 LTC facilities in
Connecticut (US)
Time period: Nov 1999 - Jan 2000
The majority of respondents agreed
or strongly agreed that an
anticoagulation service would reduce
the workload on physicians (76%),
and increase the percent of time that
nursing home residents on warfarin
are maintained in the target
therapeutic range (54%). 53%
disagreed or strongly disagreed with
statements suggesting that this
service would reduce the risk of
warfarin-related bleeding. 45% of
respondents agreed with a statement
that this service would intrude on
physician decision-making. 53% of
the respondents said they might use
an anticoagulation service for
managing their LTC patients on
warfarin. The most desirable aspects
of an anticoagulation service were
surveillance for drug interactions
(65%), scheduling of laboratory tests
(48%), management of warfarin
dosing (45%), and risk assessment for
bleeding (40%). The most frequently
cited challenges to managing
warfarin therapy in the nursing home
setting were dealing with
medications that interact with
warfarin (59%), keeping patients
within target therapeutic range
(53%), and making dosage
adjustments (30%)
Quality assessment for
observational studies:
1) Unbiased selection of
the cohort? Yes
2) Selection minimizes
baseline differences in
prognostic factors? Yes;
performed analysis of non-
responders
3) Sample size calculated/
5% difference? No
4) Adequate description of
the cohort? Yes
5) Validated method for
ascertaining exposure? No;
minimal description of
anticoagulation services
provided
6) Validated method for
ascertaining clinical
outcomes? Validation of
new questionnaire not
reported
7) Outcome assessment
blind to exposure? NA
8) Adequate follow-up
period? Yes; cross-sectional
9) Completeness of follow-
up? Yes
10) Analysis controls for
confounding? No; cross
tabulation with subject
attributes not performed
11) Analytic methods
appropriate? No; statistical
error (CIs) reported in only
some findings
Funding: Centers for
Medicare and Medicaid
Services, Department of
Health and Human
Services; AHRQ
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3Table 3 Prescriber attitudes and concerns with warfarin use (Continued)
Monette et
al. (1997) [29]
To assess the knowledge and
attitudes of physicians regarding the
use of warfarin for stroke prevention
in patients with AF in LTC facilities
Design: cross-sectional study
Data source: survey questionnaire of
2 clinical scenarios with substantial
contrasts in patient characteristics:
1) 94-year old male resident with
chronic AF, ischemic heart disease,
CHF and osteoarthritis, no history of
falls, independent in activities of daily
living;
2) 80-year old female with recent
stroke with resulting hemiplegia and
dysarthria, having chronic AF, CHF,
CAD, hypertension, diabetes, and
chronic renal insufficiency, with
cognitive deficits and entirely
nonambulatory
Population: 269 physicians were
asked to participate in the survey;
182 (67.7%) completed the
questionnaire
Setting: 30 LTC facilities located in
New England, Quebec, and Ontario
(US and Canada)
Time period: Feb 1995 to Jul 1995
Only 47% of respondents indicated
that the benefits of warfarin greatly
outweigh the risks in this setting; the
remainder of physicians indicated
that benefits only slightly outweigh
the risks (34%) or that risks outweigh
benefits (19%). The most frequently
cited contraindications to warfarin
use were: excessive risk of falls (71%),
history of GI bleeding (71%), history
of non-CNS bleeding (36%), and
history of cerebrovascular
hemorrhage (25%). Among the 164
physicians who reported using the
INR to monitor warfarin therapy, 27%
indicated a target range with a lower
limit < 2.0, 71% indicated a target
range between 2.0 and 3.0, and 2%
indicated an upper limit > 3.0.
Among respondents who answered
questions about the clinical scenarios,
estimates of the risk of stroke
without warfarin therapy and the risk
of intracranial hemorrhage with
therapy varied widely
Quality assessment for
observational studies:
1) Unbiased selection of
the cohort? Yes
2) Selection minimizes
baseline differences in
prognostic factors? No;
analysis of non-responders
was not performed
3) Sample size calculated/
5% difference? No
4) Adequate description of
the cohort? Yes
5) Validated method for
ascertaining exposure? Yes;
conducted pre-testing to
establish content validity
6) Validated method for
ascertaining clinical
outcomes? No further
assessment validity
conducted for new
questionnaire
7) Outcome assessment
blind to exposure? NA 8)
Adequate follow-up
period? Yes; cross-sectional
9) Completeness of follow-
up? Yes
10) Analysis controls for
confounding? Yes
11) Analytic methods
appropriate? No; statistical
error (CIs) reported in only
some findings
Funding: Dupont Pharma
AF, atrial fibrillation; AHRQ, Agency for Healthcare Research and Quality; CAD, coronary artery disease; CHF, congestive heart failure; CI confidence interval; CNS, central nervous system; GI, gastrointestinal; INR,
international normalized ratio; LTC, long-term care; NA not available.
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3warfarin therapy before the study period and those who
did not have a history of stroke were more likely to
maintain INR values within the therapeutic range. Karki
et al. [31] observed that a group of LTC residents with
INR fluctuations > 0.99 between blood samplings
received more medications known to interact with war-
farin vs a group with INR fluctuations ranging from 0.5-
0.99. Verhovsek et al. [22] found that residents receiving
interacting medications spent less time in therapeutic
range. Time in therapeutic range varied significantly
among prescribing physicians [22].
Potential warfarin interactions
The three studies cited above [22,30,31] (Table 4 Part A)
also evaluated the use of potentially interacting medica-
tions among residents receiving warfarin for any condition
(n = 302). Aspinall et al. [30] reported that 89% of resi-
dents were receiving a medication that potentially interacts
with warfarin. The most common agents were omeprazole
(51% of residents), simvastatin (45%), aspirin (34%), citalo-
pram (18%), and levothyroxine (13%). Karki et al. [31]
reported that 46% of LTC residents were prescribed a
potentially interacting agent during the study period. Ver-
hovsek et al. [22] found that 79% of residents were pre-
scribed more than one warfarin-interacting medication
during a 12-month period; most common were acetami-
nophen (40% of residents), citalopram (25%), aspirin
(16%), diltiazem (11%), and simvastatin (10%).
Quality assessment
Overall, in the nine warfarin management and monitoring
studies described above (Table 4 Parts A and B), methodo-
logical quality was low to moderate. Low power was com-
mon: five studies [9,22,23,30,31] had an insufficient
number of subjects to find 95% significance for an odds
ratio of 1.5. Four studies [22-24,30] had either inadequate
descriptions of resident follow-up or insufficient follow-up
periods to achieve the stated study purpose. Seven studies
[9,11,22-25,31] had deficiencies either in adequately ana-
lyzing or reporting study findings or in accounting for
potential confounders.
Warfarin-related Adverse Events
Two studies [25,26] (Table 5) sought to evaluate adverse
warfarin-related events in the LTC population (n =
17,429). In a study of 25 nursing homes, Gurwitz et al.
[25] determined the combined overall rate of adverse
warfarin-related events (18.8 per 100) and potential
adverse warfarin-related events (6.6 per 100) to be 25.5
per 100 resident-months on warfarin therapy. Of the
adverse warfarin-related events, 11% were deemed ser-
ious and 2% were life-threatening or fatal. Overall, 29% of
the adverse warfarin-related events were considered pre-
ventable; of the serious, life-threatening, and fatal events,
over half (57%) were considered preventable. Quilliam et
al. [26] explored an association between warfarin and the
antiplatelet agents (excluding clopidogrel, which was not
yet available) and risk of hospitalization for bleeding
among LTC residents. After adjustment for demographic
characteristics and medications, use of warfarin, com-
pared to no warfarin or antiplatelet medication, was asso-
ciated with a significantly increased risk of hospitalization
for bleeding. Recipients of warfarin plus aspirin were
more likely to be hospitalized for a CNS bleeding event;
recipients of warfarin alone were more likely to be hospi-
talized for a GI bleeding event.
Quality assessment
Except for limitations in one study, which neither ade-
quately controlled for confounding nor explored the asso-
ciation of poor INR control with warfarin-related adverse
events or resident characteristics [25], methodological
quality for these two adverse event studies was acceptable.
Discussion
Results from this review show that AF, DVT, PE, and
stroke prevention in residents without AF, account for
nearly all warfarin use in the LTC setting [24,25]. Of these
four, AF is the primary indication for warfarin use,
accounting for the majority, or as many as three of every
four residents receiving this agent in LTC [24,25].
Suboptimal anticoagulation among patients with AF
Current consensus guidelines, including those of the
American College of Chest Physicians (ACCP) [32-34],
American College of Cardiology/American Heart Associa-
tion/European Society of Cardiology (ACC/AHA/ESC)
[35], and the ESC alone [36], strongly support the use of
warfarin in patients with AF who have one or more high
risk factors or two or more moderate risk factors for
stroke, especially among those not at high risk for bleed-
ing. The American Medical Directors Association
(AMDA) guidelines for stroke management in LTC,
updated in 2011, also recommend warfarin as primary
therapy for stroke prophylaxis in AF, but suggest that a
systematic assessment of stroke and bleeding risk be per-
formed prior to initiation of therapy [2]. Lau et al. in this
review found that nearly all LTC residents with AF were
at high risk for stroke simply because 88% of residents
were ≥ 75 years of age[10].
Current AMDA guidelines cite a general low use of
warfarin in residents with AF who have no contraindica-
tions for its use [2]. Evidence from five LTC studies in
our review suggests a pattern of improving but still low
rates of warfarin use in AF: among LTC residents with
AF studied since 1997, between 46% and 60% were pre-
scribed warfarin [7,10,11]; in earlier studies dating to the
mid-1990s, only 17% to 32% received warfarin [8,9]. Our
findings suggest that bleeding risk alone may not explain
the low rates of warfarin use for AF in LTC. Even among
candidates described as having high stroke risk and low
Neidecker et al. BMC Geriatrics 2012, 12:14
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Page 25 of 33Table 4 Warfarin management and monitoring
Study Study objective,
(intervention/exposure
and outcomes)
Study design,
data source
Study population,
study setting,
time period
Results Quality assessment,
funding Source
Part A: Quality of oral anticoagulant prescribing and monitoring
Aspinall et al.
(2010) [15,30]
To describe the quality of
warfarin prescribing and
monitoring in VA nursing
homes and to assess
factors associated with
maintaining a therapeutic
INR
Design:
retrospective
cohort study
Data source:
medical record
review
Population: all veterans (160)
who received warfarin
Setting: 5 VA nursing homes
(US)
Time period:
Jan 1, 2008 - June 30, 2008
INRs were in therapeutic range for 55% of
the 10,380 total person-days of warfarin. In
a 4-week period, patients had an average of
5.2 (SD = 2.7) INRs obtained. 99% of the INR
tests were repeated within 4 weeks of the
previous result. 49% of patients had INRs in
the target range for ≥ 50% of their person-
days. Achieving this outcome was more
likely in patients with prevalent warfarin use
than with new use (adjusted OR = 2.86;
95% CI = 1.06-7.72). Patients with a history
of a stroke (adjusted OR = 50.38; 95% CI =
50.18-0.80) were less likely to have
therapeutic INRs for > 50% of their days.
Approximately 89% of the patients at
baseline were receiving ≥ 1 medication that
potentially interacts with warfarin. The most
frequently prescribed interacting drugs at
baseline were omeprazole (51% of patients),
simvastatin (45%), aspirin (34%), citalopram
(18%), and levothyroxine (13%). During the
study period, 46% of patients were
prescribed a medication with the potential
to interact with warfarin
Quality assessment
for observational studies:
1) Unbiased selection of the cohort? Yes
2) Selection minimizes baseline differences in
prognostic factors? Yes
3) Sample size calculated/5% difference? No
4) Adequate description of the cohort? Yes
5) Validated method for ascertaining exposure? Yes
6) Validated method for ascertaining clinical
outcomes? Yes
7) Outcome assessment blind to exposure? Yes
8) Adequate follow-up period? Partial; length of
follow-up not clearly stated in Methodology
9) Completeness of follow-up? Yes
10) Analysis controls for confounding? Yes
11) Analytic methods appropriate? Yes
Funding: various VA centers and US government
agencies
Gurwitz et al.
(2007) [25]
(repeated from
table 1)
The percentages of time in the < 2, 2-3,
and > 3 INR ranges were 36.5%, 49.6%, and
13.9%, respectively
Gurwitz et al.
(1997) [8]
(repeated from
table 1)
Of 122 warfarin users with adequate INR
data, warfarin therapy was monitored at
least every 2 weeks in 52% of the subjects,
every 2-4 weeks in 32% of the subjects, and
less frequently than every 4 weeks in only
16% of the subjects. On average, 117 NVAF
residents with available INR data were
maintained in the therapeutic range 39.6%
of the time, in the subtherapeutic range
44.8% of the time, and in the
supratherapeutic range 15.6% of the time; <
23 subjects (20%) were in the therapeutic
range ≥ 60% of the time
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3Table 4 Warfarin management and monitoring (Continued)
Karki et al. (2003)
[31]
To evaluate the warfarin
management patterns in
an academic nursing
home and evaluate what
pre-determined factors
are associated with
variability in the INR
Design: case
control study
Data source:
medical chart
review
Population: 37 residents
receiving warfarin therapy for
> 3 consecutive months in a
calendar year
Setting: 566-bed academic
medical center nursing home
(US)
Time period: 12-month period;
dates not specified
For patients who had INR values exceeding
the therapeutic range there was no
significant difference between “easy”
management (INR fluctuations of 0.5-0.99
and outside therapeutic range ≤ 10% of
time, n = 18) and “difficult” management
(with INR fluctuations > 0.99 and outside
therapeutic range > 10% of time, n = 19) in
all factors examined. The “difficult
management” group received more
medications known to interact with warfarin
than the “easy” management. These
medications may have caused the INR to
increase above the normal range (P=0.003),
as well as produced large (P=0.001) or small
fluctuations (P=0.0007) in the INR. 54% of
residents on warfarin therapy initiated a
potential warfarin-interacting drug. Of all
interacting medications, 55% were
antibiotics and 28% were analgesics
Quality assessment
for observational studies:
1) Unbiased selection of the cohort? Partial; limited
to residents of a single nursing home
2) Selection minimizes baseline differences in
prognostic factors? Yes
3) Sample size calculated/5% difference? No; very
low power
4) Adequate description of the cohort? No; only
limited description of nursing home and resident
characteristics reported
5) Validated method for ascertaining exposure? No;
assignment of subjects to “easy management” and
“difficult management” cohorts not validated
6) Validated method for ascertaining clinical
outcomes? Yes
7) Outcome assessment blind to exposure? Yes
8) Adequate follow-up period? Yes
9) Completeness of follow-up? Yes
10) Analysis controls for confounding? Partial;
evaluated association of age, gender, and number
of illnesses with cohort
11) Analytic methods appropriate? Partial; only
limited univariate analyses conducted
Funding: not stated
Lackner et al.
(1995)[9] (repeated
from table 1)
The INR was within the recommended
range for NVAF over a 6-month period 37%
of the time and recommended PT, 52% of
the time. An equal percentage of warfarin
dose changes occurred in response to a PT
ratio outside the recommended range as
occurred with an INR outside the
recommended range
McCormick et al.
(2001) [11]
(repeated from
table 1)
In the 42% of AF patients who were
receiving warfarin therapy, the therapeutic
range of INR values was maintained only
51% of the time, was below the therapeutic
range 36% of the time, and was above the
therapeutic range 13% of the time
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3Table 4 Warfarin management and monitoring (Continued)
Verhovsek et al.
(2008) [22]
To determine how
effectively warfarin was
administered to a cohort
of residents in LTC
facilities by measuring
TTR, to identify the
proportion of residents
prescribed warfarin-
interacting drugs and to
ascertain factors
associated with poor INR
control
Design:
Retrospective
cohort study
Data source:
medical chart
review
Population: 105 LTC residents
receiving warfarin therapy
Setting: 5 LTC facilities in
Hamilton, Ontario (Canada)
Time period: 12 months of
data for each resident
between October 2004 and
April 2005
3065 INR values were available. Residents
were within, below, and above the
therapeutic range 54%, 35% and 11% of the
time, respectively. 79% of residents were
prescribed ≥ 1 warfarin-interacting
medication during the period in review. The
5 most common drugs were
acetaminophen (40% of residents),
citalopram (25%), acetylsalicylic acid (16%),
diltiazem (11%), and simvastatin (10%).
Residents receiving interacting medications
spent less TTR (53.0% vs 58.2%, OR = 0.93;
95% CI = 0.88-0.97, P=0.002). Adequacy of
anticoagulation varied significantly between
physicians (TTR range 45.9-63.9%)
Quality assessment
for observational studies:
1) Unbiased selection of the cohort? Yes
2) Selection minimizes baseline differences in
prognostic factors? Yes
3) Sample size calculated/5% difference? No; low
power for both residents and physicians studied
4) Adequate description of the cohort? Yes
5) Validated method for ascertaining exposure? Yes
6) Validated method for ascertaining clinical
outcomes? Yes
7) Outcome assessment blind to exposure? Yes
8) Adequate follow-up period? Partial; some
residents may have had < 6 month follow-up of
INR
9) Completeness of follow-up? Yes
10) Analysis controls for confounding? No;
association of INR outcomes with subject attributes
not analyzed
11) Analytic methods appropriate? No; analysis of
residents limited to simple one-way tabulations
Funding: CIHR and the Regional Medical Associates
Part B: Medication management interventions
Allen et al. (2000)
[23]
To evaluate the
effectiveness of nurse
practitioner management
of anticoagulation using
a protocol. Outcomes
were frequency of blood
draws as well as
frequency and
percentage of INRs that
were out of range
Design:
retrospective
cohort study
Data source:
nurse practitioner
maintained
records
Population: 47 patients on
long-term anticoagulation
therapy
Setting: 9 area nursing homes
(US)
Time period: 6 months
beginning June 1997
Average number of venipuncture ranged
from 0.7 -2.7 per month. Reasons for out-of-
range INRs were identified 35% of the time.
Percentage out of range was 15%
Quality assessment
for observational studies:
1) Unbiased selection of the cohort? Cannot be
determined; convenience sample of 47 residents
2) Selection minimizes baseline differences in
prognostic factors? Yes
3) Sample size calculated/5% difference? No
4) Adequate description of the cohort? No; resident
characteristics not described
5) Validated method for ascertaining exposure? Yes
6) Validated method for ascertaining clinical
outcomes? Yes
7) Outcome assessment blind to exposure? No
8) Adequate follow-up period? Cannot be
determined; post-intervention follow-up period not
described
9) Completeness of follow-up? Cannot be
determined
10) Analysis controls for confounding? No; no
evaluation of association of resident attributes with
INR outcomes
11) Analytic methods appropriate? No; Statistical
error not reported
Funding: not specified
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3Table 4 Warfarin management and monitoring (Continued)
Papaioannou et al.
(2010) [24]
(repeated from
Table 1)
Overall, TTR increased during the MEDeINR
phase (65-69%), but was significantly
increased for only 1 facility (62-71%, P<
0.05). The percentage of time in
supratherapeutic range decreased from 14%
to 11%, P=0.08); there was little change for
the subtherapeutic range (21% to 20%,
P=0.66). Overall, the average number of INR
tests per 30 days decreased from 4.2 to 3.1
(P< 0.0001) per resident post-
implementation. Feedback from LTC
clinicians and staff indicated that the
program decreased workload, improved
confidence in management and decisions,
and was generally easy to use
CI, confidence interval; CIHR, Canadian Institute of Health Research; INR, international normalized ratio; LTC, long-term care; NVAF, nonvalvular atrial fibrillation; OR, odds ratio; PT, prothrombin time; SD, standard
deviation; TTR, time in therapeutic range; VA, Veteran’s Administration
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3Table 5 Warfarin-related adverse events
Study Study
objective,
(intervention/
exposure and
outcomes)
Study design, data
source
Study population, study
setting, time period
Results Quality assessment,
funding source
Gurwitz et al.
(2007) [25]
(repeated from
Table 1)
720 warfarin-related AEs and 253 potential warfarin-related AEs were
identified. Of the warfarin-related AEs, 87% were characterized as minor,
11% were deemed serious, and 2% were life-threatening or fatal. Overall,
29% of warfarin-related AEs were judged to be preventable. The rate of
warfarin-related AEs was 18.8 per 100 resident-months on warfarin
therapy (95% CI, 17.5-20.3 per 100 resident-months), with a rate of 5.4
preventable warfarin-related AEs per 100 resident-months (95% CI, 4.7-6.2
per 100 resident-months). Potential warfarin-related AEs occurred at a rate
of 6.6 per 100 resident-months on warfarin (95% CI, 5.8-7.5 per 100
resident-months). Serious, life-threatening, or fatal events occurred at a
rate of 2.5 per 100 resident-months (95% CI, 2.0-3.0 per 100 resident-
months); 57% of these more severe AEs were considered preventable.
Errors resulting in preventable AEs occurred most often at the prescribing
and monitoring stages of warfarin management
Quilliam et al.
(2001) [26]
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and 126, respectively. The odds of a CNS bleed with aspirin use was 1.36
(95% CI = 1.05-1.78) and 1.64 (95% CI = 1.19- 2.26) for warfarin use. The
number needed to treat for harm values for CNS; bleeds were 534 (95%
CI = 214- 3846) for aspirin and 301 (95% CI = 153-1012) for warfarin.
Patients with GI bleeding were more likely to have taken warfarin (OR =
1.18; 95% CI = 1.03-1.36); number needed to treat for harm, 228 (95% CI
= 114- 1366). Aspirin users were not more likely to be hospitalized for GI
bleeds (OR = 1.01; 95% CI = 0.91- 1.14)
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3bleeding risk, rates of warfarin use among LTC residents
with AF in three studies were 20% [10], 53% [11], and
60% [10].
Physician concerns illustrate resistance to using warfarin
Physician concerns may, in part, explain low observed
warfarin use in the LTC setting. Surveys of physicians
using case-study examples showed that respondents
strongly supported use of antiplatelet agents [27]. How-
ever, these same respondents appeared reluctant to pre-
scribe warfarin for the case-study residents, each of whom
had AF plus one or more major risk factors for stroke.
Only half of surveyed physicians agreed that benefits of
warfarin therapy greatly outweigh the risks [29]. Specific
concerns motivating physicians to avoid using warfarin
seem clear, starting with risk of falls in two studies (71%
and 98%) [26,28], and including dementia [27], short life
expectancy [27], history of GI bleeding [29], history of
other non-CNS bleeding [29], and history of cerebrovascu-
lar hemorrhage [29].
Consensus noted among some factors associated with
use of warfarin
In this review, several factors were associated with greater
u s eo fs t r o k ep r e v e n t i o nt h e r a p y –AF in stroke survivors
[12,18], history of stroke [7,8] in residents with AF, hyper-
tension [12,18] in stroke survivors, and depression [12,18]
in stroke survivors. Dementia and severe cognitive impair-
ment were generally associated with lower use or initiation
of stroke prevention therapy in LTC [8,12,18]. Previous GI
bleeding was also strongly and negatively linked to use of
warfarin or antiplatelets in patients with AF and in stroke
survivors [7,12].
This review also found that black race was generally
associated with lower, adjusted use of therapy. Although
one study [7] did not find a significant multivariate asso-
ciation between African-American race and use of war-
farin or antiplatelets in stroke survivors, the number of
observed subjects (n = 117) may have been too small to
adequately test this factor. Three other studies [12,17,18]
that examined the same therapies in strongly powered
multivariate models found evidence of a significantly
lower use of these agents among black compared with
white stroke survivors.
Conflicting findings or no evidence of association were
found across studies for other resident characteristics
and use of stroke prevention therapy: age ≥ 85 years
(reduction or no association), coronary artery disease
(increase or no association), dependent physical func-
tioning (reduction or no association), peptic ulcer dis-
ease (reduction or no association), high overall bleeding
risk (reduction or no association), and overall stroke risk
(no association).
Warfarin management and monitoring signal that INR
levels remain difficult to maintain
Studies in this review consistently showed that in LTC
residents receiving warfarin, INRs are in the target
range approximately half of the time [8,9,11,22,25,30].
With further evidence that only one in five residents
exceed 60% of monitored time in therapeutic range [8],
achieving INR targets is a potentially serious problem in
the LTC setting. Comparing mean values reported in
this review, residents who fall out of target range are
2.5-3 times more likely to have INR levels that are sub-
therapeutic, which exposes them to a potentially greater
risk of stroke, rather than supratherapeutic, which
would increase their bleeding risk. Studies in this review
suggest that blood draws in LTC occur frequently
[8,30], at least once per month for 84% or more of resi-
dents [8,30], and more often for many residents [23,24].
McCormick et al. [11] discuss the seeming paradox in
the controlled-care environment of LTC where such
INR control problems often occur. Although non-adher-
ence to medication or INR monitoring poses fewer pro-
blems in the LTC setting, and despite potentially better
control of interacting medications and diet, warfarin
prescribing and INR monitoring appear less than opti-
mal [11].
Several factors may be associated with reduced time in
INR therapeutic range. These include history of stroke
[30] and medication interactions [22,31]. Regarding the
latter, evidence from this review suggests that the
opportunity for warfarin interactions in the LTC facility
is great, with 46-89% [22,30,31] of residents taking a
potentially interacting medication.
The two studies that evaluated medication manage-
ment systems [23,24] reported substantially higher post-
intervention times in target range than those discussed
above. However, in one of these studies [24], the use of
an electronic decision support system for warfarin dos-
ing produced no significant gain across facilities in time-
in-range when compared to the pre-intervention period.
Findings from the second study [23] showed that 85% of
post-intervention INR draws were within range; how-
ever, these results are largely uninterpretable, since the
study lacked pre-intervention data or a separate control
group.
Although no study to date has established a link
between poor INR control and health outcomes in LTC,
warfarin-related adverse events are common in the LTC
facility: the combined overall rate of adverse warfarin-
related events and potential adverse warfarin-related
events was high, equivalent to one adverse effect for
every 4 months on therapy [25]. The use of warfarin was
also associated with a significantly increased risk of hos-
pitalization for a bleeding event [26].
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Consensus guidelines regarding the use of warfarin for pri-
mary or secondary stroke prevention in AF may not be
sufficiently followed in the LTC setting, where warfarin
use appears suboptimal. The challenges of warfarin use in
the LTC setting are apparent to physicians and, in their
view, may outweigh the benefits of stroke risk reduction.
For LTC residents who are receiving warfarin, maintaining
therapeutic INR remains problematic, even in the highly
controlled LTC environment. Further research is needed
to evaluate appropriate use of anticoagulants in this set-
ting, including a more explicated consideration of the
appropriate balancing of risks and benefits in an important
but problematic issue for the geriatric clinician.
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